

UMR 599 Centre de Recherche en Cancérologie de Marseille





Institut de Cancérologie et d'Immunologie de Marseille

Analysis and annotation of the transcriptional regulatory sequences of higher eukaryotes: the point of view from the wet lab

Après-midi thématique séquences de régulation transcriptionnelle IRISA – Rennes – Jeudi 11 janvier 2007

Jean Imbert Equipe Régulations Transcriptionnelles









For a European Research Initiative: http://fer.apinc.org/

Si vous aviez des doutes sur l'intérêt de la chose...

The Human Genome



From Bing Ren, Laboratory of Gene Regulation, Ludwig Institute for Cancer Research, UCSD



Genome-wide comparison of transcriptional activator families in eukaryotes

C2H2 zinc fingers are found in 2% of all human genes, and they are by far the most abundant class of DNAbinding domains found in human transcription factors.

From Tupler R, Perini G, Green MR. Nature 409: 832-833, 2001.

Cancer Associated Transcription Factors

NAME CANCER TYPE

AL5Q31	acute lymphoblastic leukemia
ASCL1	small cell lung cancer (SCLC)
BCL3	B-cell l eukemi a
BCL6	B cell lymphoma
CBFB	m yel oid leukemia
CBL	pre-B and pro-B cell lymphomas
CTNNB1	Colon cancer
DEK	Leukemi a, acute nonlymphocytic
ERG	Acute myelcidleukemia (AML)
ETS1	erythroblastosis
ETS2	erythroblastosis
ETV6	AML
FOS	murine osteosarcoma
FKHR	rhabdomyosarcoma
GAS41	Glioma
GLI	Glioma
HOX11	Leukemi a
IRF2	AML
IRF4	multiple myeloma
JUN	murine osteosarcoma
LMO2	Acute T-cell l eukemi a
LYL1	T-cell leukemi a
MAF	multiple myeloma
MLL	AML
MYB	Leukemi a
C-MYC	Lymphoma, Breast Cancer, lung cancer
N-MYC	neuroblastoma

NAME	CANCER TYPE
NFKB1	Acutelymphoblasticleukemia
NFKB2	B-Cell lymphom a
PAX3	alveolar rhabdomyosarcoma
PAX5	B-Cell lymphom a
PAX7	alveolar rhabdomyosarcoma
PBX1	leukemia
RARA	AML
REL	Diffuse large cell lymphoma
RELA	Diffuse large cell lymphoma
RUNX1	Leukemia, acute myeloid
SPI1	acute murine erythroleukemia
STAT3	Leukemi a
TAL1/SCL	T cell l eukemia
TAL2	T cell l eukemi a
TCF3	Acute leukemi as
BLIMP1	B-cell non-Hodgkin lymphoma
E2F1	Murine Reproductive tract sarcomas
IRF1	AML
MAXII	prostate adenocarcinoma
PML	Acute promyelocytic leukemia
RB1	retinoblastoma
SMAD3	colorectal cancer
SMAD4/DPC4	pancreatic carcinoma; juvenile polyposis
TFE3	renal cell carcinom a
TP53	Colorectal cancer and other types
WT1	Wilm s tumor
ZF9/KLF6	prostate cancer

From Bing Ren, Laboratory of Gene Regulation, Ludwig Institute for Cancer Research, UCSD

Comment définir un gène et ses séquences régulatrices ?

CORE PROMOTER



TATA Box: TATAAAA (about 25 base pairs upstream of the start point)

Initiator (Inr): PyPyCAPyPyPyPy

MODEL OF TYPICAL GENE PROMOTER AND REGULATORY REGIONS



cis-acting regulatory elements

From Pennacchio, L. A. and E. M. Rubin. 2001. Genomic strategies to identify mammalian regulatory sequences. Nat. Rev. Genet. 2:100-109.

Promoter: Sequence of DNA near the 5' end of a gene that acts as a binding site for RNA polymerase and from which transcription is initiated.

Enhancer: Control element that elevates the levels of transcription from a promoter, independent of orientation or distance.

Locus control region (LCR): Confers tissue-specific temporally regulated expression of linked genes. LCRs function independently of position, but they are copy number dependent and open the nucleosome structure so that other factors can bind. LCRs affect replication timing and origin usage.

Boundary element/insulator: DNA sequence that prevents the activation or inactivation of transcription by blocking the effects of surrounding chromatin.

Silencer: Control element that suppresses gene expression independent of orientation or distance.

Matrix attachment region (MAR)/scaffold attachment region (SAR): DNA sequence that binds the nuclear scaffold and can affect transcription. These elements probably form higher-order looped structures within chromosomes and influence gene expression by separating chromosomes into regulatory domains.

Ça se complique encore...





CHROMATIN REMODELING COMPLEXES

Modified from Jones and Kadonaga, Genes Dev. 14:1992-1996, 2000.

Human Genome

Lander et al. (2001) Nature 409: 860-921

Table 21 Characteristics of human g	enes	
	Median	Mean
Internal exon	122 bp	145 bp
Exon number	7	8.8
Introns	1,023 bp	3,365 bp
3' UTR	400 bp	770 bp
5' UTR	240 bp	300 bp
Coding sequence	1,100 bp	1,340 bp
(CDS)	367 aa	447 98
Genomic extent	14 kb	27 kb
iman Genome size : 3 G	ю	x 35 k genes
imary transcripts (pre-	mRNA) : 1 Gb	
tergenic DNA: 2 Gb	2,000,000	probes at 1 kb resolutio
rediction of promoting r	regions (1st ex	on) ?

La Londe les Maures 12 May 2005. Rémi Houlgatte « Chromatin Profiling of Human Pathologies »

TOOLS FOR THE IDENTIFICATION OF REGULATORY SEQUENCES AND THEIR COGNATE TRANSCRIPTION FACTORS

1. Identification and characterization of regulatory sequences

- Gene reporter assays: transient or stable transfection (CAT, Luciférase, SEAP, GFP, β -gal, etc.)
- In vitro transcription assay
- Sequencing, database mining (web: TESS, Euk. Pr. Database, TRANSFAC, MATINSPECTOR, TFSEARCH, etc.)
- Animal or cellular models: enhancer trap, enhancer knock-in, minichromosomes, etc.

2. Identification and characterization of specific transcription factors (TFs)

- EMSA and sequels: UV-crosslinking, pull-down assay using biotynilated oligonucleotide
- Footprint detection:
 - * *in vitro :* nucleases (DNAse I hypersensitivity, S1 nuclease, Mmase) or chemical compounds
 - * *in vivo* : genomic footprinting, Chromatin ImmunoPrecipitation (ChIP) and sequels

3. TFs physical and functional interactions

- Transfection and biochemistry
- ChIP-on-chip

L'analyse des séquences....

Promoter Regulatory Elements: Features and Facts

- Degenerate sequence motifs
- Length: 6 to 20 bp
- Low complexity (8-12 bits)
- Binding sites of transcription factors
- Excess of binding sites over binding proteins in the nucleus
- Most in vitro binding sites not functional in vivo
- Some in vivo binding sites also not functional
- Regulatory potentials depends on cooperative effects between multiple elements

CpG islands

- CpG dinucleotides are present at 20% of predicted frequency
- CpG islands: >200 bp long, >50 %G+C, CpG >0.6 predicted
- CpG islands account for 1% of the genome
- 29,000 CpG islands are predicted in the human genome
- ~60% of known genes have a CpG island near 5' end
- CpG island microarrays are promoter- and regulatory region-enriched arrays

29,000 CpG islands are predicted in the human genome

Weinmann et al. (2002) Genes & Dev. 16:235-244 Oberley et al. (2004) Methods Enzymol. 376:315-334

CpG Island Localization



La Londe les Maures 12 May 2005. Rémi Houlgatte « Chromatin Profiling of Human Pathologies »

Regulatory information is encoded in the DNA...



... and can be uncovered by phylogenetic footprinting



Transcription Factors Tend to Bind to Proximal Promoter Regions



From Bing Ren, Laboratory of Gene Regulation, Ludwig Institute for Cancer Research, UCSD

Gene promoter regions are highly conserved between human and mouse orthologs



From Bing Ren, Laboratory of Gene Regulation, Ludwig Institute for Cancer Research, UCSD

Mais quelles sont les limites d'un gène ?

Some examples....

Control of CD25/IL-2Ra gene transcription

Kim, H. P., <u>Imbert, J.</u>, and Leonard, W.J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. *Cytokine Growth Factor Rev*, *online* doi:10.1016/j.cytogfr.2006.07.003, 2006.



CD25/IL-2R α GENE TRANSCRIPTION DURING T CELL ACTIVATION







Available online at www.sciencedirect.com



Cytokine & Growth Factor Reviews 17 (2006) 349-366



www.elsevier.com/locate/cytogfr

Survey

Both integrated and differential regulation of components of the IL-2/IL-2 receptor system

Hyoung Pyo Kim^{a,*}, Jean Imbert^b, Warren J. Leonard^a

^a Laboratory of Molecular Immunology, Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1674, United States
^b Centre de Recherche en Cancérologie de Marseille, UMR599 INSERM-Institut Paoli-Calmettes-Universite de la Mediterranee, 27 Boulevard Lei Roure, 13009 Marseille, France

Available online 5 September 2006

Abstract

Interleukin-2 was discovered in 1976 as a T-cell growth factor. It was the first type I cytokine cloned and the first for which a receptor component was cloned. Its importance includes its multiple actions, therapeutic potential, and lessons for receptor biology, with three components differentially combining to form high, intermediate, and low-affinity receptors. IL-2R α and IL-2R β , respectively, are markers for double-negative thymocytes and regulatory T-cells versus memory cells. γ_c , which is shared by six cytokines, is mutated in patients with Xlinked severe-combined immunodeficiency. We now cover an under-reviewed area—the regulation of genes encoding IL-2 and IL-2R components, with an effort to integrate/explain this knowledge. Published by Elsevier Ltd.

Keywords: IL-2; IL-2 receptor; Transcription; ye; XSCID

1: BN000945. Reports ...[gi:117414121]

Features Sequence

	LOCUS DEFINITION	BN000945 78588 bp DNA linear PRI 02-NOV-2006 TPA_exp: Homo sapiens IL2RA gene for interleukin 2 receptor, alpha, promoter region and complete CDS				
	ACCESSION	BN000945				
	VERSION	BN000945.1 GI:117414121				
	KEYWORDS	Third Party Annotation; TPA; IL2RA gene; interleukin 2 receptor, alpha; TPA; EXPERIMENTAL.				
	SOURCE	Homo sapiens (human)				
	ORGANISM	Homo sapiens				
TDA		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
		Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;				
		Catarrhini; Hominidae; Homo.				
	REFERENCE	1 second control of the second s				
BN000945	AUTHORS	<pre>Cross,S.L., Feinberg,M.B., Wolf,J.B., Holbrook,N.J., Wong-Staal,F. and Leonard,W.J.</pre>				
	TITLE	Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I				
	JOURNAL	Cell 49 (1), 47-56 (1987)				
	PUBMED	3030566				
	REFERENCE	2 and we have a character that there				
	AUTHORS	Cross,S.L., Halden,N.F., Lenardo,M.J. and Leonard,W.J.				
	TITLE	Functionally distinct NF-kappa B binding sites in the				
		immunoglobulin kappa and IL-2 receptor alpha chain genes				
	JOURNAL	science 244 (4903), 466-469 (1989)				
	PUBMED	2497520				
	REFERENCE					
	AUTHORS	Lin, B.B., Cross, S.L., Halden, N.F., Roman, D.G., Toledano, M.B. and Leonard, W.J.				
	TITLE	Delineation of an enhancerlike positive regulatory element in the interleukin-2 receptor alpha-chain gene				
	JOURNAL	Mol. Cell. Biol. 10 (2), 850-853 (1990)				
	PUBMED	2153927				

50 annotated features, including 6 regulatory regions and 44 functional regulatory elements with their cognate transcription factors
20 references (originally 28...)

Phylogenetic footprinting: two species comparison



http://pipmaker.bx.psu.edu/pipmaker/

Schwartz, S., Zhang, Z., Frazer, K.A., Smit, A., Riemer, C., Bouck, J., Gibbs, R., Hardison, R., and Miller, W. (2000). PipMaker: A Web Server for Aligning Two Genomic DNA Sequences. Genome Res. 10, 577-586.

Homo Sapiens/Mus Musculus IL-2Ra locus dotplot comparison





Percent Identity Plot (PIP) of Homo Sapiens and Mus Musculus IL-2Rα locus



Schwartz, S., Zhang, Z., Frazer, K.A., Smit, A., Riemer, C., Bouck, J., Gibbs, R., Hardison, R., and Miller, W. (2000). PipMaker: A Web Server for Aligning Two Genomic DNA Sequences. Genome Res. 10, 577-586.

Homo Sapiens versus Mus Musculus PRRI/II conservation

Local identities (aligment n°6)

8724-8798	<>	11629-11703	<mark>83</mark> %	(75	nt)
8800-8886	<>	11704-11790	76 %	(87	nt)
8887-8911	<>	11792-11816	<mark>96</mark> %	(25	nt)
8913-8946	<>	11817-11850	97 %	(34	nt)
8954-8979	<>	11851-11876	100%	5 (2 6	5 nt)
8982-8999	<>	11877-11894	83%	(18	nt)
9003-9006	<>	11895-11898	100%	5 (4	nt)
9007-9015	<>	11901-11909	78 %	(9 I	nt)
9017-9079	<>	11910-11972	70%	(63	nt)
9082-9128	<>	11973-12019	51%	(47	nt)
9129-9153	<>	12021-12045	64%	(25	nt)
9160-9202	<>	12046-12088	58%	(43	nt)
9203-9292	<>	12090-12179	73%	(90	nt)
9293-9313		10101 10001	67%	(21	





In Vivo Footprinting

- 1) Methylation of guanines (major groove) and to a lesser extent of adenines (minor groove) by DMS on living cells The level of methylation is affected by protein binding to DNA
- 2) Genomic DNA extraction
- 3) Cleavage of methylated residues by piperidine
- 4) LMP-PCR amplification of the region to be analyzed Last amplification cycles performed with a ³²P-labeled primer
- 5) Analysis of the PCR products on sequencing gel

In vivo modification of the GASd/EBSd motif occupancy in response to CD2+CD28 costimulation in purified human primary T cells


The GASd/EBSd motif is the only putative regulatory element within PRRII modified in vivo in response to an IL-2-dependent induction in human T lymphocytes **INDUCIBLE** - 3772 - 3718 **TTTCTTCTAGGAAGTACCAAACATTTCTGATAATAGAATTGAGCAATTTCCTGAT** AAAGAAGATCCTTCATGGTTTGTAAAGACTATTATCTTAACTCGTTAAAGGACTA GASd/EBSd GASp/GATA EBSp CONSTITUTIVE

Lecine, P., Algarte, M., Rameil, P., Beadling, C., Bucher, P., Nabholz, M. and <u>Imbert, J.</u> Elf-1 and Stat5 bind to critical element in a new enhancer of the human interleukin-2 receptor alpha gene. Mol.Cell.Biol. 16: 6829-6840; 1996.

Gene reporter assay



Electrophoretic Mobility Shift Assay (EMSA)

Inducibles complex C2 and C3 are GAS-specific Constitutive complex C1 is EBS-specific



CD25/IL-2Rα GASd/EBSd EMSA probe:

GASd TTTCTTCTAGGAAGTACC AAAGAAGATCCTTCATGG EBSd

TTTCTTCTGAGAAGTACC AAAGAAGACTCTTCATGG

Mouse site I

Phylogenetic footprinting and DNAse I hypersensitive site mapping



A. Homo Sapiens/Mus musculus CD25/IL-2Rα gene



Chromatin Immunoprecipitation ChIP Assay

Chromatin immunoprecipitation (ChIP)



Stat5b and Ets-1/2 bind to IL-2Ra within human IL-2rE in vivo

PRRIII ChIP primer design

1 T.	CTGCCCTTAGCTTCTACCCCTCTCTACTTCTGGTTAACTATGGACCACACTCTGCTTC	
	BZ3-1 BZ3-2	
61	CTCAGGAACCACCTACCAAGGCCGTATCCATCCTTCAAGGACAATACGTGGGCCTTTCCT	
	>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	
121	GATCACATCAGCTCAACAACTTTTCCCTCCTACATTTCAATTGCTCTTCTTACCATAATC	
	>>>	
181	ATTAGTATTCACCCCACTGTACGTCTAGAAAGAAGTGGTCTTAAACCTAAGGGAAGGCA	
241	GTCTAGGTCAGAAATTTGTTGTCCGCTGTTCTGAGCAGTTTCTTCTAGGAAGTACCAAAC	
	BZ3-3	
301	ATTTCTGATAATAGAATTGAGCAATTTCCTGATGAAGTGAGACTCAGCTTGCACTGTTGA	
	<<<<<<<<>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	
361	CCGGCTGTCCTGGATGAACCTAGTTACTTTTAACCAAATGTTCCTTTCTTGAACTTGTTC	
	<<	
421	CTTTCTTGAACTTAATCTATC	
-		

OLIGO	start	len	tm	gc%	3' seq
BZ3-1	62	20	59.96	55.00	TCAGGAACCACCTACCAAGG
BZ3-3	362	20	59.62	55.00	GGTCAACAGTGCAAGCTGAG
BZ3-2	104	20	60.71	50.00	ATACGTGGGCCTTTCCTGAT



Cela ne marche pas toujours...

A Well-Conserved but not Functional Candidate for a CD28 Responsive Enhancer

Comparison of two nucleotidic sequences: Sequence 1 : cons4HS Sequence 2 : cons4mus

resetting to DNA matrix LALIGN finds the best local alignments between two sequences version 2.0u4 Feb. 1996 Please cite: X. Huang and W. Miller (1991) Adv. Appl. Math. 12:373-381

Comparison of: (A) cons4HS (B) cons4mus using matrix file: DNA, gap penalties: -16/-4

79.6% identity in 201 nt overlap; score: 612

		NF-ATp				
	10	20	30	40	50	60
cons4H	CATAGTGGATTT	TGGT TTTCC ACG	GGACCCCTGT	GCCCTTGTCT	AGTAGAATCI	FGGTGGA
	:::::::::::	::::::::::	:::::	:::::	:::: :: ::	: :::::
cons4m	CATAGTGGATTC	TGGT TTTCC ACA	GGACCC	TGTCT	AGTAAAACCI	FAGTGGA
	10	20	30		40	50
		NF-KB/CD28R	C CREB	Ets		
	70	80	90	100	110	120
cons4H	AATTACAAACTG	C AGAAATTCAA C	TCA <mark>GTGCCGC</mark>	AATAACAGGA	TGCACCTGT#	AGAT TTC
	:::::::::::::	:::::::::::::::::::::::::::::::::::::::	::::: :	: : : : : : : : : :	::::::::::	::::::
cons4m	AATTACAAGCTG	-AGAAATTCAGC	CTTGTGCCAC	AATAACAGGA	TGCACCTGT#	AGAT TTC
	60	70	80	90	100	110
	GAS					
	130	140	150	160	170	180
cons4H	GTAGAA TTAGCA	GCAGCATTCTTT	CAATACCAGT	TTGAGAGAAA	TAACCCTGTT	FTGCATA
	::::::::	::::::::	:: ::: :	: : : : : : : : : :	:: :::::	::: :
cons4m	ACAGAA TTAGCT	GCTGTCTTCTCT	TAACGCCAAT	TTGAGAGAAA	GAAGCCTGTT	TTGTCTG
	120	130	140	150	160	170
	190	200				
cons4H	GTGCCAACTGGG	GCAGAATCT				
	::::: ::	::::::::				
cons4m	CTGCCAAACAGG	GCAGAATCT				
	180	190				

Et il y a des surprises...

The crucial CRE/TRE motif within CD25/IL-2R α PRRV/CD28rE is contained in a SINE/MIR repeat and is not conserved between *Homo Sapiens* and *Mus Musculus*

Local identities (aligment n°1)

211-245	<>	312-346	74%	(35 nt)	
261-312	<>	347-398	62%	(52 nt)	
313-322	<>	400-409	70%	(10 nt)	
323-371	<>	414-462	61%	(49 nt)	
374-388	<>	463-477	60%	(15 nt)	
389-444	<>	480-535	75%	(56 nt)	
447-482	<>	536-571	53%	(36 nt)	
491-542	<>	572-623	67 %	(52 nt)	
544-602	<>	624-682	61%	(59 nt)	
603-664	<>	684-745	66%	(62 nt)	
666-686	<>	746-766	57%	(21 nt)	
690-709	<>	767-786	85%	(20 nt)	
712-744	<>	787-819	58%	(33 nt)	

Seg 2 = ">MmIL-2Ra 12.5kb genomic fragment from phage Ch4Cl9 5'->3'" Local Alignment Number 1 Similarity Score: 12780 Match Percentage: 59 % Number of Matches: 325 Number of Mismatches: 175 Total Length of Gaps: 42 Begins at (211,312) and Ends at (744,819) 0 211 CTCTAAAAAGGTTCTGCATACAGtcattcattcaatgcttaacgactgag 312 CTTTTAAGTGGTTCTCCACAGAATCATTAATTCAA 50 261 cattaattccatgctaagtactgaactcagcactaggaataagaaggcga 347 CAGGTATCATGTGCTAGGTCCTATACTCAGAACTGAGACTAAAATGGTAA 100 311 cc tagaggcata tcctctctctaaagatgcatagagcctcattgg | -||||:| | |----|:||:|:||||||:|::||:|||||| : ::||| 397 CAATAGAAGAAGACAATTTCTTTTTCTAAAAAACACACAGAGCACAGCTGG 150 BclI : . : . : . : . : 356 aatgatcagccgtgtctcccagagagctacaagg cagTTTTCAATTGGT 447 AATTCTTGGGCATGTA CAGATTGATGGAGGGTACAGTTTTAAGTTGGT 200 404 AAATGCCCTGAGAGTGATGGGCTTGTGGCATGTGTAAgggttagacagac |||||:|:|||||: |||: |||:|| |||||:|||||--||::::: 495 AAATGTCTTGAGAGCTATGACATGGTAGCCTGTTTGAGGGT GATGATT 250 454 ctgggacctagacatgacaccactcctgacgaattatgtgagtgtgggtg |:|: ||| | |||:| ||||:-----||||| ||||:: 543 GTAGACACTACTCCTCACATCTCTCCTGG GTGAGAGTGGGCA 300 . : . : . : . : . : 504 tttcacaaccacaatgagatgcaatgcctgcacttgtaacatggaaatag 585 TTTCATAATTACAGTAAAATATAATGTCTTCATCAGCAA ATGGAAATCG 350 .SphI : : : : : : : : 554 tgatg*gcatgc*cggccccgccagattgctgtgagaagtcagcggcagag <u>|||::::||:||:||: :| |:|||||</u>||||:||||:::| |:-634 TGACAATGTGTCAGCTAGACATGGTTGCTGTGTGAAATCAGTAAGATAAC 400 . : . : . : . : . : 603 acatgcaacattctcagcacagtgcttgccatgtagtaagggcctagtca 684 ACATTAAAAATGTATGGCACAGAGCCTGCTATGTAATAAACATTTATTCA 450 653 gtgctagTGATTCCTTTCAATATTCCTAAGATGCAGATAAGGGAACAGCC 734 ATGGTAGTGGTT ATTTCCGTACTAGAGATATGC TAAGGCAACAGCT 500 . : . : . : . : |||||:|--|:||::||:|| :: ||||| :::||||:| 780 CAGAGAA GAGAATACCTCTACATAATGGGATCTGATGAAA

Seg 1 = ">HS IL-2Ra 9.3KB genomic fragment from ENSG00000134460 5'->3'"

HS4 (-8.5Kb) CD28rE (PRRV) [-8689,-8484]

BclI-SphI fgt

underlined: SINE/MIR repeat Parfois on peut aller très vite de l'ordinateur à la paillasse...

Selection of CD19 B-cell specific regulatory sequence and design of CD19-GFP lentiviral vector

Moreau, T., F. Bardin, J. Imbert, C. Chabannon, and C. Tonnelle. 2004. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol.Ther, 2004, in press.

Computational analysis of homologies between Human and Mouse CD19 gene 5' regions



A. Recombinant CD19-GFP lentiviral vectors



B. GFP expression in the progeny of transduced CD34⁺ progenitor cells differentiated in vitro



From Moreau et al., Mol.Ther, 2004.

De nouveaux outils...

Phylogenetic footprinting: multi-species comparison

Species choice for phylogenetic footprinting analysis



Homo sapiens ERBB2 locus chr17:35,092,919-35,143,441



UCSC Genome Bioinformatics: http://genome.ucsc.edu/

ESPERR Regulatory Potential (7 species): alignments of human, chimpanzee (panTro2), macaque (rheMac2), mouse (mm8), rat (rn4), dog (canFam2), and cow (bosTau2).

VISTA Tools: mVISTA and rVISTA

http://genome.lbl.gov/vista/

Frazer KA, Pachter L, Poliakov A, Rubin EM, Dubchak I. VISTA: computational tools for comparative genomics. Nucleic Acids Res. 2004 Jul 1;32 (Web Server issue):W273-9

mVISTA

Limits:

- sequence numbers: 2-100
- size: ?

Mayor C., Brudno M., Schwartz J. R., Poliakov A., Rubin E. M., Frazer K. A., Pachter L. S. and Dubchak I. (2000) VISTA: Visualizing Global DNA Sequence Alignments of Arbitrary Length. Bioinformatics, 16:1046.

ERBB2 locus



rVISTA

Limits:

- sequence numbers: 2-100
- size: 20 Kb per sequence for a total of 60 Kb

Loots, G., Ovcharenko,I., Pachter,L., Dubchak,I., Rubin, E. rVISTA for comparative sequence-based discovery of functional transcription factor binding sites. (2002) Genome. Res. 12:832-839



GATA-4: a member of the GATA family (GATA-1/6)



A. GATA-4





Current Opinion in Genetics & Development

C. GATA-3 consensus DNA binding motif

chromosomal localization 8p23.1-8p23.1*



rVISTA Homo sapiens ERBB2a-b 20kb



Homo sapiens ERBB2a regulatory regions (13,883 bases)



http://www.dcode.org/



DCODE.org Comparative Genomics Center comparing genomes to decipher the code of gene regulation

TOOLS. ECR Browser ECRbase SynoR Mulan **z**Picture multiTF rVista 2.0 eShadow Creme 2.0 Arrav2BIO

NEWS

PUBLICATIONS

ABOUT US

MAILING LIST

LINK TO DCODE!

Whole genome alignments ECR Browser -- Evolutionary conservation of multiple genomes. Identification and sequence analysis of regulatory elements. Genome Alignment -- Align your FASTA nucleotide sequence to a genome of choice.



November 7, 2006

News

Multiple and pairwise sequence alignments

detection of functional sequence patterns.

was published in Bioinformatics [PDF].

18 visitors online

Mulan -- Full multiple sequence alignment. [Interactive conservation profiles, phylogenetic trees, etc.] zPicture -- Stacked pairwise and multiple sequence alignment.

eShadow -- Phylogenetic shadowing of closely related species.

DCODE.org Comparative Genomics Center is a publicly available resourse for regulatory

"ECRbase: Database of Evolutionary Conserved Regions, Promoters, and Transcription

Factor Binding Sites in Vertebrate Genomes" manuscript describing a new Doode.org resource

genome data mining. It provides tools for evolutionary comparisons, sequence alignments, and

Identification of conserved transcription factor binding sites (cTFBS)

XVENT1_01 Excluding up to 95% false positive TFBS predictions using sequence conservation STAT_01 as a filter.



multiTF -- cTFBS in multiple sequence alignments. rVista 2.0 -- cTFBS in pairwise alignments.

Regulation of co-expressed genes



SynoR -- Prediction of synonymous regulatory elements in vertebrate genomes. Creme 2.0 -- Identification of cTFBS modules specific to promoters of co-expressed human genes.

Additional resources



Xenomics -- Xenopus tropicalis computational resources Insitu.dcode.org - Xenopus tropicalis in situ database Reverse complement a nucleotide sequence Primers/oligos selection tool Batch sequence retrieval from the UCSC Genome Browser

Google Health News

21-Dec-2006 US Teens Turning From Illigit Druas... >>> 21-Dec-2006 Gut Bacteria May Determine Dieting Efficiency >>> 21-Dec-2006 New PET Tricks for Old-Age Disease >>> 21-Dec-2006 New flu pandemic 'would kill 62 million'>>> 21-Dec-2006 Biomarkers Little Help for Heart Attacks >>> 21-Dec-2006 Health Highlights: Dec. 21, 2006 >>> 21-Dec-2006 US measles outbreak tied to traveler from Romania >>> 21-Dec-2006 Indonesia claiming bird flu success as cases drop >>>

More news from Google News

Genetics news

21-Dec-06 Researchers make progress in studying genetic traits of India-born populations >>> 21-Dec-06 Feinstein Institute and Cold

Spring Harbor Lab join forces, seek manic depressio >>>

21-Dec-06 Shotaun seauencina finds nanoorganisms >>>

21-Dec-06 Intelligent software solutions to better understand biological processes >>> 21-Dec-06 Scientists develop method to find genetic basis for plant variation >>> 21-Dec-06 What it means to be human >>> 21-Dec-06 Structure of iron regulatory protein-RNA complex solved >>> 21-Dec-06 JCI table of contents: Dec. 21, 2006 >>>

Bioinformatics news

21-Dec-06 Intelligent software solutions to better understand biological processes >>> 19-Dec-06 Plant biologist seeks molecular differences between rice and its mimic >>> 19-Dec-06 Human-chimp difference may be biager >>>

14-Dec-06 Bevond the book: Software automates access to brain atlases >>>

More news from Eurek Alert!

Comparative Genomics Center, Computation Directorate Lawrence Livermore National Laboratory



Dcode.org Mulan ECR Browser ECR Base SynoR zPicture multiTF rVista 2.0 Creme 2.0 eShadow array2BIO

ECR Browser

http://ecrbrowser.dcode.org/

D ((dad)	1	and in manif	
a mat	1. 海道	1 = 11	
المراجعة والمراجع	and and and	a links and	- 164
A FEAR N	3.3132	alust Best	r
		1	1

The <u>ECR Browser</u> is a dynamic whole-genome navigation tool for visualizing and studying evolutionary relationships between vertebrate and non-vertebrate genomes. The tool is constantly being updated to include the most recently available sequenced genomes (currently: **human**, **dog**, **mouse**, **rat**, **chicken**, **frog** two pufferfish (*Fugu* and *Tetraodon*), **zebrafish**, and **6 fruitflies**).

Evolutionary Conserved Regions (ECRs) that have been mapped within alignments of the genomes are presented in this graphical browser, which depicts and color-codes ECRs in relation to known genes that have been annotated in the base genome. '**Grab ECR**' feature allows users to rapidly extract sequences that correspond to any ECR, to visualize underlying sequence alignments and/or identify conserved transcription factor binding sites.

In addition to accessing pre-computed alignments for the available genomes, the ECR Browser can also be used as an alignment tool. It allows users to map submitted sequences to specific homologous positions within the

human, mouse, rat, chicken, *Fugu* or fruit fly genomes and to create a detailed alignment using the blastz alignment program.

Please note: Not all alignments are visible by default. Click "Browser Settings" to see all available alignments

Run the ECR Browser

Select a base organism and indicate the name of a gene or a chromosomal location (*chr1:from-to* format) Human (Mar'06) (hg18)

GENOME ALIGNMENT: Align your sequence to either Human, Mouse, Rat, Chicken, Fugu or Drosophila genome

Help

- <u>Details</u> of the alignment strategy and ECR Browser structure.
- Instructutions on how to use the ECR Browser.

Citing the ECR Browser

I. Ovcharenko, M.A. Nobrega, G.G. Loots, and L. Stubbs ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes Nucleic Acids Research, 32, W280-W286 (2004) [PDF]

Special features:

- Identification of regions of homology and significant paralogy between the base sequence and other aligned genomes: The user can retrieve locations of homologous sequences within aligned genomes and view the extent of sequence match to the base genome. <u>Details</u>.
- User-determined parameters: The browser permits the user to decide the lengths and percent identities that will be considered significant, and which
 will highlighted on the viewing screen and available for download and analysis. <u>Details</u>.
- Easy retrieval and analysis of ECR sequences and ready access to underlying alignments: In the ECR browser, conserved sequence peaks are not simply static features on a graph, but are active links that permit easy access to sequences and alignments. The user can retrieve ECR sequences and send them on for additional analysis, such as <u>rVista</u>. A tool to facilitate primer design for experimental manipulation of conserved exons, enhancers, or other elements is also provided. <u>Details</u>.
- A dynamic portal to several other sequence analysis tools (<u>UCSC Genome Browser</u>, <u>GALA</u> annotation database, <u>Ensembl</u>, <u>Rat Genome Browser</u> at <u>MCW</u>, <u>NCBI</u>, <u>zPicture</u> and <u>rVista 2.0</u> tools) providing users with a wide range of choices for detailed evolutionary analysis and follow-up studies that might include annotating novel genes using mRNA, EST and conserved sequence data or analysis of transcription factor binding sites.

About the ECR Browser

The ECR Browser was developed by Ivan Ovcharenko with help from Marcelo Nobrega, Gabriela Loots and Lisa Stubbs.

Homo sapiens ERBB2 locus chr17:35,092,919-35,143,441



G.G. Loots and I. Ovcharenko

ECRbase: Database of Evolutionary Conserved Regions, Promoters, and Transcription Factor Binding Sites in Vertebrate Genomes. Bioinformatics, 23(1):122-4 (2007)

ECR Browser (http://ecrbrowser.dcode.org/) legend

putative regulatory ECR (ECR that is conserved in all vertebrate species) gene direction ECR track gene name link to the ECR Browser home page chromosome selection bar http://ecrbrowser.dcode.org/ 19 8 9 10 11 CATA3 14 15 16 18 20 22 21 efGene dynamic 100% link to the UCSC 9 ł. Genome 50% 20 Browser 100% ¢. chromosome 50% repositioning 100% bar 10 1000 50% synteny 110 (light blue 100 100% bar) 90 CAT IN COM 50% 100% percent identity cutoffs 50% 5 19kb 10kb + 1.5x + 3x + 10x locus chromosomal - 3x -5x. - 10x Grab ECR relative position location (in red) ECR zoom in zoom out move in the base genome alignment layer height repetitive - sequences element binding sites (allow "popups" to use it) Color codes Species UTR intron intergenic coding tetraodon zebrafish mouse rat fugu element exon






multiTF: ERBB2 Hs-Md-Mm-Cf-Rm



SynoR: http://synor.dcode.org/

Synonymous gene regulation (identified by shared tissue and timepoint specificities) is established through genomic elements that contain a specific cluster of transcription factor binding sites (TFBS). SynoR performs vertebrate genome scans for evolutionary conserved clusters of TFBS in a predefined configuration to identify synonymous regulatory elements (SREs). SynoR searches for SREs by utilizing known patterns of TFBS in active regulatory elements (REs) as seeds for genome scans. Multiple-species conservation layers allow the use of differential conservation filters in the search for SREs and SynoR results provide an extensive annotation of identified genes that contain detected REs. Gene Ontology classifiers are utilized to perform functional classification of the identified genes, and integrated GNF Expression Atlas data permits on-the-fly analysis of tissue-specificities of predicted SREs.

I. Ovcharenko and M.A. Nobrega. Identifying synonymous regulatory elements in vertebrate genomes. *Nucleic Acids Research*, 33, W403-7, 2005.



Results

Request ID: s01080816575494

132 TFBS module instances identified in human (hg18) -vs- mouse (mm8) genome alignments.

Detailed modules' annotation: [table] -or- [text]

[location, length, sequence, gene type, neighboring genes, cross-species conservation analysis]

Module types:



Functional annotation of genes corresponding to noncoding modules:

- Enrichment in Gene Ontology categories: [table] and [text]

- Tissue-specificity of identified genes: <u>all noncoding</u> -or- <u>excluding distant (over 50k) elements/genes</u> (Using expression data from GNF Expression Atlas2. GNF disclaimer on data distribution.)

Chromosomal distribution (click on the image to enlarge it):

in the

Search seed:

group strand count TFBS

1 +- 1 STAT5A_01 or STAT5B_01 or STAT5A_02 or STAT5A_03

2 +- 1 ETS1_B or ETS2_B or ETS_Q4

3 +- 1 HMGIY_Q6

distance limitations: 4 .. 100

Contact Ivan Ovcharenko (ovcharenko1@llnl.gov) if you have any questions or suggestions

25 N	Aicrosoft	Excel - SynR Stat5-Ets-HMGiY s01	080816575494.xls								d 🗙
:@)	Eichier I	Edition Affichage Insertion Format	<u>O</u> utils <u>D</u> onnées Fe <u>n</u> être	2 Adobe PDF					Tapez une qu	estion 👻 .	_ 8 ×
In			🍼 । ण - ा 🖓 🧕 Σ	- 41 71 M	100%	👻 🕢 📃 i Verd	ana	• 8 • G I S = = = = = = •	% 000 € 1€	- & - A	
	G5	★ fx type						multi multisse of the second sec	in the second second		-
	A	B	С	D	E	F	G		l n	J	~
1	Request I	ID: s01080816575494									
2	7 754 (5										
3	Number	of identified clusters: 132									
4	cluster	ECR Browser cluster visualizati	on 100kb locus	TEBS map	length	# TFBS	type	dene(s)	on	sequence	
6		<u>Lot Elonosi olosion nogalizari</u>		1.1.2.2.1				•		10 NOT	1
7		1 chr1:181789037-181789076 (na) <u>locus expansion</u>	map	40 bps	6	utr	SMG7	<u>fasta</u>		
8	5	2 chr4:158504077-158504128 (na) <u>locus expansion</u>	<u>map</u>	52 bps	5	utr	GRIA2	<u>fasta</u>		-
9	5	3 chr8:113304592-113304677 (na) <u>locus expansion</u>	map	86 bps	4	utr	CSMD3	<u>fasta</u>		
10	-	4 <u>cnr4:400/4612-460/4631 (na)</u> 5 chr1:202034888-202035030 (na)	locus expansion	map	20 Dps 143 hps	4	nromoter	ZC3H11A(0.1kb)	facta		
12		6 chr9:90983553-90983680 (na)	locus expansion	map	128 bps	4	promoter	SHC3(0.1kb)	fasta		~
40		34 cbr21:37080630-37080777 (pa)	locus evnension	man	148 hps	5	introp	HICS	faeta		
41	\$	35 chr3:71618586-71618740 (na)	locus expansion	map	155 bps	8	intron	FOXP1	fasta		
42		36 chr5:15699657-15699740 (na)	locus expansion	map	84 bps	3	intron	FBXL7	fasta	1	
43		37 chr7:50532131-50532171 (na)	locus expansion	map	41 bps	3	intron	DDC	<u>fasta</u>	1	
44	2	38 chr11:106779785-106779804 (n	a) <u>locus expansion</u>	map	20 bps	6	intron	CWF19L2	<u>fasta</u>		
45		39 chr2:80243565-80243711 (na)	locus expansion	map	147 bps	4	intron	CTNNA2	tasta fasta		2
40		40 <u>cnr16:61740257-61740299 (na)</u> 41 chr10:97803892-97803996 (na)	locus expansion	map	43 Dps 105 bps	5	intron	CONI	<u>lasta</u> facta		
48		42 chr2:44610663-44610731 (na)	locus expansion	map	69 bps	3	intron	C2orf34	fasta	-	<u></u>
49		43 chr1:112092387-112092436 (na) locus expansion	map	50 bps	4	intron	Clorf183	fasta		
50		44 chr9:16672557-16672595 (na)	locus expansion	map	39 bps	5	intron	BNC2	fasta		
51		45 chr2:60620383-60620419 (na)	locus expansion	<u>map</u>	37 bps	7	intron	BCL11A	fasta		
52		46 chr3:108909610-108909657 (na) <u>locus expansion</u>	<u>map</u>	48 bps	4	intron	BBX	<u>fasta</u>		<u></u>
53	3	47 <u>cnf6;91000587-91000619 [na]</u> 48 chr17:51803726 51803799 (na)	locus expansion	map	33 DDS	8	intron	BACHZ ANKENI	<u>Tasta</u> facta	-	<u></u>
55		49 chr19:23101930-231020/99 (na)	locus expansion	man	130 bps	3	intron	AK131472	fasta		<u></u>
56		50 chr15:82125436-82125509 (na)	locus expansion	map	74 bps	4	intron	ADAMTSL3	fasta	-	
57		51 chr17:29116651-29116678 (na)	locus expansion	map	28 bps	4	intron	ACCN1	fasta		
58		52 chrX:136758449-136758530 (na) locus expansion	map	82 bps	3	intergenic	ZIC3(276.5kb)<->AK055382(766.0kb)	fasta		
59	2	53 chr1:22451484-22451501 (na)	locus expansion	map	18 bps	4	intergenic	WNT4(109.3kb)<->ZBTB40(199.4kb)	fasta		
61	1	54 <u>Cnfb:43060464-43660461 (na)</u>	locus expansion	map	10 Dps	5	intergenic	VEGF(18.3KD)<->MGC45491(195.8KD) TSPAN6(1 7kb)<->SPPX2(5.6kb)	facta		
62	2	56 chr6:138268062-138268109 (na)) locus expansion	map	48 bps	3	intergenic	TNFAIP3(21.9kb)<->PERP(185.5kb)	fasta		
63	2	57 chr13:60405544-60405573 (na)	locus expansion	map	30 bps	4	intergenic	TDRD3(359.5kb)<->PCDH20(476.2kb)	fasta	0	
64		58 chr12:114160327-114160386 (n	a) locus expansion	map	60 bps	6	intergenic	TBX3(554.0kb)<->THRAP2(720.4kb)	fasta		
65		59 chr17_random:1705583-170566	7 locus expansion	map	85 bps	6	intergenic	TBC1D3C(339.2kb)<->KPNA2(7.4kb)	fasta		
66	3	60 chr17:60168094-60168120 (na)	locus expansion	map	27 bps	3	intergenic	SMURF2(79.2kb)<->AK126557(24.6kb)	fasta		
68	2	61 <u>Chrb: 116626106-116626237 (ha</u> 62 chr7:84634924 84635051 (na)	<u>Iocus expansion</u>	map	132 DDS	3	intergenic	SEMAGA(687.5KD)<->D1WD2(1575.9KD)	<u>Tasta</u>		
69		63 chr7:83773092-83773109 (na)	locus expansion	map	18 bps	3	intergenic	SEMA3A(111.2kb)<->SEMA3D(689.7kb)	fasta		
70	ľ	64 chr21:15181852-15181906 (na)	locus expansion	map	55 bps	6	intergenic	SAMSN1(304.3kb)<->NRIP1(73.5kb)	fasta		
71		65 chr3:135516998-135517033 (na) locus expansion	map	36 bps	8	intergenic	RYK(64.7kb)<->AMOTL2(39.8kb)	fasta	-	
72		66 chr6:45817447-45817503 (na)	locus expansion	map	57 bps	5	intergenic	RUNX2(190.7kb)<->CLIC5(156.7kb)	fasta		
73		67 chr8:93548464-93548518 (na)	locus expansion	map	55 bps	7	intergenic	RUNX1T1(390.9kb)<->BC110326(416.5kb)	fasta	-	
74		69 chrs.120196607-20196661 (na) 69 chrs.133256478-133256592 (na)	locus expansion	map	75 DDS 115 bos	4	intergenic	KPS6KA3(3.7KD)<->CNKSR2(1103.8KD) RPS12(76.1kb)<->LOC285735(206.2kb)	facta	2	
76	2	70 chr5:96990947-96990966 (na)	locus expansion	man	20 bps	4	interaenic	RIOK2(446.2kb)<->RGMB(1141.9kb)	fasta		1
14 4	> H\Fe	euil1 / Feuil2 / Feuil3 /		TUMP	0.0000000000	(2)	<		14014	-	
Prêt	1.5						100			NUM	
0	dóma	Fran C Provenue		and Long a	19 A.	1 Annual			0.0.0.0.0		20105
	uemai	Mer Jolatortisri	Regurea	auvet	alle de rec	C Apresental	un 🧶 P0				22:06



ZC3H11A(0.1kb)



IL2RA(7.0kb)<->RBM17(19.6kb)

SynoR :: Tissue specificity of genes with noncoding elements

Request ID: <u>s01080816575494</u>

List of tissues, in which genes are overexpressed or suppressed: Some overexpression

olfactory bulb, spinal cord, superior cervical ganglion, uterus corpus, cerebellum peduncles, parietal lobe, cerebellum, caudate nucleus, appendix, tongue, prefrontal cortex, hypothalamus, skeletal muscle

Some suppression

subthalamic nucleus, ciliary ganglion, thymus, lymph node, fetal lung, kidney, whole blood, pancreas, fetal liver, placenta

Significant suppression

tonsil, colorectal adenocarcinoma







MAR-Wiz

http://futuresoft.org/MAR-Wiz/

The MAR-Wiz tool aims at discovering the presence of Matrix Association Regions, or MARs, within DNA sequences. MARs constitute a significant functional block within sequences and facilitate the processes of differential gene expression and DNA replication. Our computational approach to finding MARs is based upon the co-occurrence of 20 DNA patterns that have been known to occur in the neighborhood of MARs. These motifs are used to define higher order rules defined using the various combinations in which the patterns have been known to co-occur. The mathematical density of the rule occurrences iin a regions is assumed to imply the presence of a MAR in that region

For examples:

-- Cai S, Lee CC, Kohwi-Shigematsu T. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet.38:1278-88, 2006.

- P. PK, O. Bischof, P. K. Purbey, D. Notani, H. Urlaub, A. Dejean, and S. Galande. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus. *Nat Cell Biol.* 9 (1):45-56, 2007.

Cai S, Lee CC, Kohwi-Shigematsu T. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet.38:1278-88, 2006.



Figure 8. Summary of activation-dependent looping events and a model of transcriptionally active chromatin.

P. PK, O. Bischof, P. K. Purbey, D. Notani, H. Urlaub, A. Dejean, and S. Galande. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus. *Nat Cell Biol.* 9 (1):45-56, 2007.



Figure 4. SATB1 and PML directly associate with specific genomic regions of MHC class I locus *in vivo*.

MAR-Analysis Summary Report

Sequence Description: Hs II.2RA Sequence Length: 78588 Maximum and Minimum Potential = [0.0125264 ... 43.1201]

-

High S	coring l	Regions	with 1	thresho	$\mathbf{Id} = \{$	1,6
			_			

Average Strength	Integrated Strength
0.890511	802.35
	Average Strength 0.890511

-

Frequency of Rule Matches

	Number of R	tules Selected = 6	1.11
Rule Name	Forward Strand Match Count	Reverse Strand Match Count	
ORI Pattern	512	505	View Detail Locations
TG-Richness Pattern	18	20	View Detail Locations
Curved DNA Pattern	106	106	View Detail Locations
Kinked DNA Pattern	110	110	View Detail Locations
Topo II Pattern	217	210	View Detail Locations
AT-Richness Pattern	872	849	View Detail Locations





Affymetrix ID

PDB Id

Taken from Eccented

Reactome Pathway

Talen for Reactance

n bi

Convert

Protein Level

Functional Level

PDB

GenBank Accession

Taken from UhiGane

Embl

Taken from Encented

KEGG Pathways

Takin trum KEOO

Please note that while working with thousands of ids, the process may take several minutes to conclude.

Internation available for Hamamonity

A.

S 10

u Di

Clone ID

Tallan Burn Uni Gena

SwissProt

Taken from Enamole

OMIM[®]

Takes from Example

GO. Taken Forn Responded

PubMed id Taken #sm NC81

÷

			Dor	Level			(The	te Level	Per lim
Gene Name	Ensembl Gene	Unigene Chuster	EntrezCene	Ensembl Location Chr. stari- end (strand)	UCSC Location Chr. start- end (strand)	Ensembl* Location Chr. start- end (strand)	GenBanh Accession	Clene Id	KEGG
ILIPA	R31500000134450	10 231367	3200 🕲	Caracterian 10 60926555- 414429459 (-1)	1. Constant (2012) - 201	Chemicsonie 20 60036 Shp. 614620-0p.(-1)	-		3x x0400 3x x0400 3x x0400

* Club on the different IDs for more information.

* The protein information displayed is the one corresponding to the Gare Name showm. * Only upto 20 Chine like or GenBack Assessions are listed, is see the full list get your results on a spreadsheet the or follow the (...) this.

* Fentering UniCene claster identifiest, keep in mind that UniCene retires identifiers quite offers. Club on the link on the UniCene column to know the new identifies.



and comments to the Wilmanne - latter Jugarthin, 2006

IPI.

Taken from Ensembl

Reactome Reaction

Taken from Reastorne

KEGG: hsa04630



Galaxy at Penn State University

Center for Comparative Genomics and Bioinformatics

Galaxy features connections to <u>UCSC Table Browser</u>, <u>EnsMart</u>, and contains hundreds of tools.

Some examples:

- Extraction of multiple alignments corresponding to a genomic region,
- Finding exons overlapping SNPs, compute phastCons scores for a set of genomic ranges,
- Building histograms, compute correlations, draw scatterplots, search using simple conditional statements
- And <u>much much</u> more...

Galaxy website

http://www.bx.psu.edu/cgi-bin/trac.cgi

Genomatix

http://www.genomatix.de/

DiAlign TF: Multiple alignment plus TF sites

								08/18/06 15:19:51
<u>Genomatix</u>	Eecsecal	Pasawata	4 16	() () () () () () () () () () () () () (Laga		GEMS	Launcher
Genoma	tixPortal GEA	IS Launcher	ElDorado	Gene2Pro	moter	MatBas	•	
	FAQ	Results	Sequences	Protocol	Help	N		
working on Bt_Erbb2_	GEN distal_promoter.seq	t\$ Launcher Task: (, Hs_Erbb2_distal_ i-Md_Erbb	Division TF: Multiple promotor.seq. Nm .2_distal_promotor.s	alignment plus Ti Erbb2_distal_pro Log (5 soq.)	F sites motor.seq, i-	Cf_Erbb2_d	stal_promo	ter.seq.
		(Align	menti (Pairwise simila	attest				
								and the second
DiAlign professional TF Release 3.1.1	September 2005						Fri	Aug 18 15:14:64 2006
DiAlign professional TF Release 3.1.1 Solution parameters: Sequence file:	September 2005 <u>Br. Erob2</u> I-MA Ero	distal promoter seg	Ha Erbb2 datel or	amoler ang Mm. B	into2_distal_s	ramoler seg	Fri	Aug 12 15:14:54 2000
DiAlign professional TF Release 3.1.1 Solution parameters: Sequence file: Type of acquences:	1 September 2005 <u>Bt. Erob2</u> I-MALEro nucleolide	distal promoter sea 52 distal promoter a sequences	. <u>Ha Erbb2 distel pr eg</u> (5 seq.)	amoler ang Mm_E	into2_distal_s	remoler ses	Fri	Aug 12 15:14:54 2000
DiAlign professional TF Release 3.1.1 Solution parameters: Sequence file: Type of sequences: Threached T:	September 2005 <u>Et Erobo</u> <u>I-Md Erb</u> nucleotide 0.00	distal promoter seg 22 distal promoter s sequences	. <u>Ha Erbb2 distel or ad (5 seq.)</u>	amaler seg .htm_E	intet2_distai_s	romoler seg.	Fri	Aug 12 15:14:54 2001 distal_promoter sep
DiAlign professional TP Release 3.1.1 Solution parameters: Sequence file: Type of sequences: Threshold T: "signs below alignment denote:	September 2005 <u>Et Erobo</u> <u>I-Md Eto</u> nucleotide 0.00 diagonal t	distal promoter seg 12 distal promoter a 13 sequences cinitarity (max. simila	: <u>Ha Erbb2 datal or</u> <u>alo</u> (5 seq.) vRy 15 represented by	omoler seg Mm <u>-</u> E 10 signs;	ith2 distal s	romöler seg.	Fri	Aug 18 15:14:54 2004 distal_promoter sep
DiAlign professional TF Release 3.1.1 Solution parameters: Sequence file: Type of sequences: Threachold T: " signs below alignment denote: Alignment output:	Exptember 2005 EX. Emb2 IMM Em nucleotide 0.00 diagonal to compete # nucleot	distal promoter beg 52 distal promoter a sequences imitarity (max. simila alignment is shown scide per ime: 50	. <u>Hs. Erbb2: dotel or</u> <u>eng</u> (5 seq.) vRy is represented by	omoler seg. Mm_E 10 signs)	ito2_dala(_s	romoler seg	Fri I-Cf Erbo2	Aug 19 15:14:64 2004
DiAlign professional TF Release 3.1.1 Solution parameters: Sequence file: Type of sequences: Threshold T: " signs below alignment denote: Alignment output: TF output:	Exptender 2005	distal promoter seq c2 distal promoter a sequences unitarity (max. simila alignment is shown acids per line: 50 T matches located b	: <u>Hs Erbb2 datel or ag (5 seq.)</u> rRy is represented by n aligned regions (co	omoler seg .htm_E 10 signs) mmon to 4 (00.0 %	itio2_disla(_s	romoler ses.	Fri	Aug 18 15:14:64 2004
DiAlign professional TF Release 3.1.1 Solution parameters: Sequence file: Type of sequences: Threshold T: " signs below alignment denote: Alignment output: TF output: Family matches:	Exptender 2005 <u>Rr. Emb2</u> <u>IMd. Exb</u> muteotide 0.00 diagonal compete a nucleic commen yes	distal promoter sea 52 distal promoter a sequences unitarity (max. simila adjumment is shown icida per line: 50 17 matches located in	(<u>Hs Erbb2 datal or</u> <u>etg (5 seq.)</u> rRy is represented by n aligned regions (co	amoler sea Mm. E 10 signa) mman to 4 (80.0 %	inbo2_distaf_s	romoler ses	Fri	Aug 19 15:14:64 2004 datal promoter sea
DiAlign professional TP Release 3.1.1 Solution parameters: Sequence file: Type of sequences: Theshold T: "signs below alignment denote: Alignment output: TF output: Farrily matches: Mainspector library:	Beptember 2005 Bt. Emb2 LiMd. Env nucleotide 0.00 diagonal s complete # nucleic complete # nucleic complete # nucleic complete # nucleic complete # nucleic complete # nucleic diagonal s complete # nucleic diagonal s complete monti s complete # nucleic diagonal s complete monti s complete complete s complete s complete s complete s complete s complete complete s complete	distal promoter sea 02 distal promoter a sequences unitarity (max. simila alignment is shown cick per line: 50 FF matches located is mity Library Version I	. <u>Hs. Enbb2 datal or</u> <u>ing</u> (5 seq.) vity is represented by n aligned regions (co s.1 (June 2006)	amoler seg. <u>Mm. F</u> 10 signa) mmon to 4 (80.0 %	(1662 distat s	romöler seg.	Fri	Aug 18 15:14:64 2004

Aligned Sequences:

No	Sequence Name	Sequence Description	Length
	t besTau2_dna	bosTeu2_dna range=ctrr19.32329406-32231721 5/pad=0 3/pad=0 revComp=FALSE strand=7 repeatMasking=none	2316 bp
	2 hg18_dna	hg18_dna tange~ctr17.35095702~35098500 Spad=0 Spad=0 revComp=FALSE strand=? repeatMasking=none	2879 bp
	Second dria	mm8 dna range=chr11 98214976-98217649 Spad=0 3pad=0 revComp=FALSE strand=7 repealMasking=none	2674 bp
	t canFam2_dna	canFam2_dna range=chr8 28120323-28123005 Spad=0 3pad=0 sevComp=FALSE strand=7 sepastMasking=nonejcomm=reverse complement	2678 bp
	monDom4_dna	monDom4_dna tange=chr2:198109436-198125765 5/pad=0 3/pad=0 revComp=FALSE strand=7 repeatMasking=none(commiseverse complement	16331 bp

Alignment (DiAlign format):

Please note that only upper-case letters are considered to be aligned. For more information, please have a look at the user guide.

0003	of the local division of	USPAKE VEZ	FHX VE	SPIE 12	A SCAAT	ORIGINAL USE	THE VEPAXS	VALUE VAZERE

| | 1 | | | | | | | ٦ | 1 |
 | | | | | |
 | 2 | 1 | | | | | | | 3

 | 1 | |
 | | | |
 | | 4 | 1
 | |
 | | | | | |
|----|---------------------------------------|---|--|--|---|---|---|--|--
--|---|---|--|---
--|---|--|---|---|---|--|---
--|--
--
---|--|---
--
---|---|---|---|--
---	--
--	---
--	---
1	τ.
 | Ġ, | A C | 10 | C | A. | c ·
 | t. | 11 | T | т | G / | 10 | ; C | τ | T

 | ¢ | c | τ
 | G (| S A | G | 6
 | T. | A | G /
 | 6.1 | 3 0
 | 3 0 | : 0 | À | × | c |
| 1 | Τ.1 | 1 9 | Ci | ė A | ĊΤ. | 0.0 | G A | A | c | т
 | G) | A 0 | i G | 0 | A | c '
 | ť. | г т | ġ. | T. | | 4 0 | c c | T | T

 | c | 0 | Ŧ.
 | G.(| a A | G | G
 | τ. | A | G /
 | A (| G (
 | 2.0 | 0 | A | A | c |
| 11 | 1.1 | 0 1 | CO | C A | T. | 0. | A D | A | c | т
 | a / | A C | 10 | c | A | 0
 | T I | C 1 | a | T. | a (| 3 0 | c c | c | т

 | c | C | τ.
 | G a | | | G
 | T. | | ά,
 | A 1 | G C
 | 50 | 10 | A | A | c |
| 1 | 11 | 0 | 00 | C A | T | 0 | a A | . A | C | T
 | ġ, | A. 10 | 0 | C | | c -
 | r i | гī | G | т | 3/ | 10 | c c | T | т

 | c | C | 1
 | T C | 5.A | a | 6
 | T. | | ۵ /
 | 6.1 | 8 6
 | 3.0 | 10 | A | A | C |
| 1 | T | 0 | CO | 0.0 | T | 6 | A A | A | c | t
 | σ. | A. 0 | 0 | ٨ | A | 5
 | T | C 1 | 0 | Ţ | A / | 10 | c | Ŧ | T

 | C | C | Ţ
 | 0 0 | 3.4 | 6 | 6
 | Ť. | A | 8
 | A 1 | 5 0
 | 5 0 | . 0 | C | ٨ | c |
| | 2.2 | | | | 2 | | | - | 2 | 2
 | | | - | 2 | |
 | | | 1 | 1 | | | | 2 | 2

 | 2 | 2 |
 | 2.2 | 1 | 2 | 2
 | 1 | 2.5 | 2.2
 | |
 | 10 | | 2 | | 2 |
| | | | | ., | + | | | | | 2
 | | | | | |
 | | | + | + | | | | |

 | | |
 | | - | | +
 | | |
 | č, |
 | | | + | | |
| | | | | | | | | ٠ | | ٠
 | | | | | | 6.1
 | | | ٠ | ٠ | | | | ٠ |

 | ٠ | |
 | | | ٠ | ۰.
 | • | |
 | |
 | | ٠ | ٠ | ٠ | | | | | | |
| | | | • • | | * | | | | * |
 | • • | • | | ٠ | • • |
 | • | • • | + | + | • • | • | | ٠ |

 | ٠ | ٠ | •
 | | | ٠ | +
 | • | • |
 | 9 | • •
 | 1.5 | | ٠ | ٠ | ٠ |
| | | | | | | • • | | . • | | •
 | • | <u> </u> | | | • • |
 | ×) | • • | | ۰. | • • | | . * | ۰. |

 | * | ۰. | •
 | • • | | ٠ | +
 | • | * | • •
 | 1 |
 | | • | ٠ | ٠ | ٠ | | | | | |
| | | | | | | | | | |
 | | | | | |
 | | | | • | • | | | 1 |

 | - | 1 | ۰.
 | | | ۰. | ۰.
 | | 1 |
 | |
 | 10 | 1 | | 1 | | | | | | |
| | | | | | | | | | |
 | | | | | |
 | | | | | . 7 | | | |

 | | 1 | |
 | | 2 | 2 |
 | | |
 | | C
 | 12 | 2 | C | 2 | 2 | | | | | |
| | 5 | | | | | | | -6 | 1 |
 | | | | | |
 | 7 | | | | | | | | 商

 | 1 | | |
 | | | |
 | | 0 |
 | |
 | | | | | | | | | | |
| 51 | 6 | s t | 8. | | | C / | A C | | |
 | C 1 | | | | |
 | 4 | | 1. | | 0.1 | | 1.2 | C. | 0

 | Ť | C | 5
 | C I | | C | A
 | 6 | 6 |
 | |
 | | C | C | | 6 | | | | | |
| 51 | a | | - | | 2 | - | | | |
 | | 1 | | - | N |
 | | | | | | | | - |

 | т | - | 2
 | | | - |
 | | | -
 | 2 |
 | 10 | ٤. | - | | - |
| 51 | | | | 1 | | | | | - | 1
 | | | - | - | |
 | A. I | n 1 | T | | c / | | <u>ат</u> | c | 0

 | ÷ | e. | -
 | | | - |
 | | |
 | 3 |
 | | | | ÷ | |
| 64 | | | | | 2 | 2 | | | - | Ξ.
 | 23 | | | | 2 |
 | | | | ÷ | - | | | ÷. | 0

 | 4 | ~ | 2
 | | 97 | 2 |
 | 8 | |
 | 9 |
 | | 1. | 2 | 4 | - |
| 64 | | | | | - | ~ | 10 | | + | 0
 | | | | 2 | |
 | 10 | | | R | | æ | œ | | 1

 | ÷ | 2 | -
 | ~ 1 | | | 10
 | | | 2.3
 | 9 |
 | | 82 | 2 | ÷. | |
| | 11 | | 1 | | 2 | ~ . | 27 | 0 | 2 | 7
 | | ۰. | - | - | |
 | | | | - | | | | | 2

 | 2 | 7 | ~
 | | 1 | 1 |
 | | |
 | |
 | | | - | | - |
| | | | | | | | | | | 2
 | | | | | |
 | | | | | | | | |

 | | | |
 | | | |
 | | 2. |
 | |
 | | | | | | | | | | |
| | | | | | | | | | |
 | | | | | |
 | | | | | | | | |

 | | | |
 | | | |
 | | |
 | |
 | | | | | - 21 |
| | | | ÷., | | | | | | | ۰.
 | | | | | • |
 | • | | . • | ۰. | •.• | | | |

 | | • | •
 | • • | | | •
 | • | * 1 | ••
 | . 1 |
 | | | . • | | • |
| | :: | : | :: | : | ; | : : | | : | : | :
 | : : | | ; | : | : : |
 | 1 | | ÷ | - | | | : | : | 1

 | : | ; | :
 | | : | 1 | :
 | : | 2 | 1
 | 1 |
 | 1 | ; | : | : | 2 |
| | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 1
1 T 1
1 T 1
1 T 1
1 T 1
1 T 1
1 T 1
5 1
5 1
5 1
5 1
5 1
5 1
5 1
5 | 1
1 TT 0
1 T | 1
1 TT 0 C 0
1 T | 1
1 T T G C C A
1 T T G C C A
5 1
5 1
5 1
5 1
5 1
5 1
5 1
5 1 | 1
1 TT G C C A T
1 TT G C C A T
5 1
5 1
5 1
5 1
5 1
5 1
5 1
5 1 | 1
1 TT GCC AT G
1 TT GCC GT G
1 TT GCC GT G
5 1
5 1
5 1
5 1
5 1
5 1
5 1
5 1 | 1
1 TT GCCAT GGA
1 TT GCCAT GA
5 1
5 1
5 1
5 1
5 1
5 1
5 1
5 1 | 1 1 1 1 1 0 C A T G G A A
1 T T G C C A T G G A A
1 T T G C C A T G G A A
1 T T G C C A T G G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T T G C C A T G A A
1 T G C A T G A A C C A C
5 1 G T G A C C C A C
5 1 A G T G A A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A G C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T G A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C A C C C A C
5 1 G T C C C A C C C A C
5 1 G T C C C A C C C C C C C C C C C C C C C | 1 11
1 TT GCCAT GGA AC
1 TT CCCGT GAA AC
1 TT CCGT GAA AC
5 1 61
5 | 1 11
1 TT GCC AT GGA ACT
1 TT GCC GT GA ACT
3 TT GCC GT GA ACT
5 1 6 1 6 1
5 1 6 1 6 1
5 1 6 1 6 1
5 1 6 1
5 1 6 1
5 1 7 1 7 3 ACC AC
5 1 7 1 7 1 7 3 ACC AC
5 1 7 1 7 1 7 1 7 3 ACC AC
5 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1 | 1 11
1 TT G C C AT G G A A C T G J
1 TT G C C AT G G A A C T G J
1 TT G C C AT G G A A C T G J
1 TT G C C AT G G A A C T G J
1 TT G C C AT G G A A C T G J
1 TT G C C G T G A A C T G J
5 1 G G T G A C C C A C A T A C J
5 1 G G T G A C C C A C A T A C J
5 1 G T G A C C C A C A T A C J
5 1 A D T G A A C C C A C A T A C J
5 1 G G T G A C C C A C A T A C J
5 1 A D T G A A C C C A C A T A C J
5 1 G G T G A C C C A C A T A C J
5 1 A D T G A A C C C A C A T A C J
5 1 G T G A C C C A C A T A C J
5 1 G T G A C C C A C A T A C J
5 1 G T G A C C C A C A T A C J
5 1 G T G A C C C A C A T A C J
5 1 G T G A C C C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A T A C J
5 1 G T G A C C C A C A C A C A C A C A T A C J
5 1 G T C A C C A C C A C A C A C A C A C A C | 1 11
1 TT GCCAT GGA ACT GAO
1 TT CCCGT GAA ACT GAO
1 TT CCCGT GAA ACT GAO
1 TT CCGT GAA COA
51 GT GA CCCAC
51 GT GA CCCAC
51 ACT GAA CCAC
51 ACT GAA CCAC
51 ACT GAA CCAC
51 OCT GA GCCAC
51 | 1 17
1 TT GCC AT GGA ACT GAGG
1 TT GCC GT GAA ACT GAGG
1 TT GCC GT GAA ACT GAGG
5 1 01
5 1 00
5 | 1 11
1 TT GCCAT GGA ACT GAGGC
1 TT GCCGT GAA ACT GAGGA
5 1 6 1 6 1
5 1 6 1 6 1
5 1 6 1 6 1
5 1 6 1 7 0 A CCCAC
5 1 A T ACA CT C
5 1 A T A CA CT C | 1 11
1 TT GCCAT GGA ACT GAGGCA
1 TT CCCGT GAA ACT GAGGCA
1 TT CCCGT GAA ACT GAGGCA
5 1 6 1
5 1 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 | 1 11
1 TT GCCAT GGA ACT GAGGCAC
1 TT GCCAT GAA ACT GAGGCAC
1 TT GCCAT GAA ACT GAGGAAC
3 TT CCCGT GAA ACT GAGGAAC
5 T GCT GACCCAC
5 1 01
5 1 00
5 1 01
5 1 00
5 1 01
5 1 00
5 1 01
5 1 00
5 1 | 1 11 2 1 1 TT GCCAT GGA ACTGAGGCAC T 1 1 TT GCCAT GGA ACTGAGGCAC T 1 TT GCCAT GGA ACTGAGGCAC T 1 TT GCCAT GGA ACTGAGGCAC T 1 TT GCCAT GGA ACTGAGGCAC T 1 TT GCCAT GGA ACTGAGGCAC T 1 TT GCCAT GGA ACTGAGGCAC T 1 TT GCCGT GAA ACTGAGGCAAC T 51 GGTGACCCGT GAA ACTGAGCGAAC T 51 GGTGACCCCAG ATACA CTCAT 51 GTGAGCCCAC ATACA CTCAT 51 GTGAGCCCAC ATACA CTCAT 51 GTGAGCCCAC ATACA CTCAT | 1 11 21 1 1 TT GCCAT GGA ACT GAGGCAC TTT 1 1 TT GCCAT GGA ACT GAGGCAC TTT 1 TT GCCAT GGA ACT GAGGCAC TTT 1 TT GCCAT GGA ACT GAGGCAC TTT 1 TT GCCAT GGA ACT GAGGCAC TTT 1 TT GCCAT GGA ACT GAGGCAC TTT 1 TT GCCAT GGA ACT GAGGCAC TTT 1 TT GCCAT GGA ACT GAGGCAC TTT 1 TT GCCGT GAA ACT GAGGCAAC TCT 1 TT GCCGT GAA ACT GAGGCAAC TCT 51 GT GACCCAC AT ACA CT CAT 51 OT GACCCAC AT ACA CT CAT | 1 11 21 1 TT GCCAT GGA ACT GAGGCAC TTTT TT GCCAT GGA ACT GAGGCAC TTTT 1 TT GCCAT GGA ACT GAGGCAC TTTT TT GCCAT GGA ACT GAGGCAC TTTG 1 TT GCCAT GGA ACT GAGGAGC TCTG 1 TT GCCGT GAA ACT GAGGAGC TCTG 1 TT GCCGT GAA ACT GAGGAGC TCTG 1 TT GCCGTGACCAC 1 TT GGGTGACCCAC 1 TT GGGTGACCCAC 1 GT GACCCAC 1 GT GACCCAC 1 A GT GACCCAC 1 A GT GAGCCACC 1 A GT GAGCCACC 1 GT GAGCCACC | 1 1 T 21 1 T T G C C A T G G A A C T G A G G C A C T T T T T 1 T T G C C A T G G A A C T G A G G C A C T T T T T 1 T T G C C A T G G A A C T G A G G C A C T T T G T 1 T T G C C A T G G A A C T G A G G C A C T T T G T 1 T T G C C A T G G A A C T G A G G C A C T T T G T 1 T T G C C A T G G A A C T G A G G C A C T T T G T 1 T T C C C G T O A A A C T G A G G C A C T C T T T 1 T T C C C G T O A A A C T G A G G C A C T C T G T 1 T T C C C G T O A A A C T G A G G C A C T C T T T 1 T T C C C G T O A A A C T G A G G C A C T C T G T 1 T T C C C G T O A A A C T G A G C C A C T C A T 5 1 6 T G A C C C C A C T 5 1 6 T G A C C C C A C T 5 1 A T A C A C T C A T 5 1 A T A C A C T C A T 5 1 A T A C A C T C A T 5 1 A T A C A C T C A T 5 1 A T A C A C T C A T 5 1 A T A C A C T C A T 5 1 A T A C A C T C A T 5 1 A T A C A C T C A T 5 1 | 1 11 21 1 1 TT GCCAT GGA ACT GAGGGCAC TT TT TT GC 1 TT GCCAT GGA ACT GAGGCAC TT TT TT GC 1 TT GCCAT GGA ACT GAGGCAC TT TT GC 1 TT GCCAT GGA ACT GAGGCAC TT TG TG 1 TT GCCAT GGA ACT GAGGCAC TT GT GG 1 TT GCCAT GGA ACT GAGGCAC TT GT GGGGGAG 1 TT GCCGT GAA ACT GAGGCAC TT GT GAGCAC 1 TT GCCGT GAA ACT GAGGCAAC TT GT GAGCAC 1 TT GCCGT GAA ACT GAGGCAAC TT GT GAGCAC 51 GOT GACCCAC AT ACA CT CAT ACT T ACA 51 GOT GACCCAC AT ACA CT CAT ACT T ACA 51 OT GACCCAC AT ACA CT CAT ACT T ACA 51 OT GACCCAC AT ACA CT CAT ACT T ACA 51 OT GACCCAC AT ACA CT CAT ACT T ACA 51 OT GACCCAC AT ACA CT CAT ACT T ACA | 1 11 21 1 1 TI GCCAT GGA ACT GAGGCAC TITITGCAT 1 TI GCCAT GGA ACT GAGGCAC TITITGCAT 1 TI GCCAT GGA ACT GAGGCAC TITITGCAT 1 TI GCCAT GGA ACT GAGGCAC TITIGCAT 1 TI GCCAT GGA ACT GAGGCAC TITIGCAT 1 TI GCCAT GGA ACT GAGGCAC TITIGCAT 1 TI CCCGT GAA ACT GAGGCAC TITIGCAT 1 TI CCCGT GAA ACT GAGGAAC TITITGCAT 51 GT GACCCAC AT ACA CICAT ACT T ACA 51 GT GACCCAC AT ACA CICAT ACT T ACA 51 GT GACCCAC AT ACA CICAT ACT T ACA 51 AT ACA CICAT ACT T ACA ACT T ACA 51 AT ACA CICAT ACT T ACA ACT T ACA 51 AT ACA CICAT ACT T ACA ACT T ACA 51 AT ACA CICAT ACT T ACA ACT T ACA 51 AT ACA CICAT AT ACA ACT ACT AT ACT T | 1 11 21 1 1 TT GCCAT GGA ACT GAG BCAC T TT TT GCAT GGA 1 TT GCCAT GGA
 ACT GAG BCAC T TT TT GCAT GGA 1 TT GCCAT GGA ACT GAG GCAC T TT TT GCAT GCA 1 TT GCCAT GGA ACT GAG GCAC T TT TT GCCAT GCA 1 TT GCCAT GGA ACT GAG GCAC T TT GCCAT GCA 1 TT GCCAT GCA ACT GAG GCAC T TT GT GACC 1 TT GCCAT GCA ACT GAG GCAC T TT GT GACC 1 TT GCCGT GAA ACT GAG GCAC T TT GT GACC 1 TT GCCGT GAA ACT GAG GCAC T TT GT GACC 51 GT GACCCCAC AT ACA CT CAT ACT T A CA GT 51 GT GACCCAC AT ACA CT CAT ACT T A CA GT 51 GT GACCCAC AT ACA CT CAT ACT T A CA GT 51 GT GACCCAC AT ACA TT CAT ACT T A CA GT 51 GT GACCCAC AT ACA TT CAT ACT T A CA GT 51 GT GACCCAC AT ACA TT CAT ACT T A CA GT < | 1 11 21 1 1 TT GCCAT GGA ACT GAGGCAC TTT TT GACCT 1 TT GCCAT GGA ACT GAGGCAC TTT TT GACCT 1 TT GCCAT GGA ACT GAGGCAC TTT GACCCT 1 TT GCCGT GAA ACT GAGGCAC TT GT GACCT 1 TT GCCGT GAA ACT GAGGCAAC TC TT GT ACCT 1 TT GCCGT GACA ACT GAGCAAC TC TT GT AACCT 1 TT GCGGT GACCAC ACT GAGCAAC TC T GT AACCT 51 GO TGACCCAC AT ACA CT CA T 51 GO TGACCCAC AT ACA CT CA T 51 AT ACA CT CA T ACT T CA TC 51 OT GAGCCAC AT ACA CT CA T 61 T T ACA CT T ACA T <td>1 11 21 3 1 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCGT GAA ACT GAGGCAC TTTGT GACCT T 1 TT CCCGT GAA ACT GAGGCAC TTTGT ACT T 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACT T 1 TT CCCGT GAA ACT GAGGAAC TTTTGT ACT T 51 GT GACCCAC AT ACACT CAAT 51 GT GACCCACC</td> <td>1 11 21 31 1 1 TT GCCAT GGA ACT GAGGCAC TTT TT TT GCCAT GGA ACT GAGGCAC TTT GCCAT GGA ACT GAGGCAC TTT GT GACCT TC 1 TT GCCAT GGA ACT GAGGCAC TTT GT GACCT TC TT TT GCCAT GGA ACT GAGGCAC TTT GT GACCT TC 1 TT GCCAT GGA ACT GAGGCAC TT TT GT GACCT TC TT TT GT GACCCT TT TT GT GACCCAC TT <</td> <td>1 1.1 2.1 3.1 1 1.TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCC 1 TT GCCGT GAA ACT GAGGCAC TTTGTAACCT TCC 1 TT GCCGT GAA ACT GAGGCAC TTGT ACACT TCC 1 TT GCCGT GAA ACT GAGGCAC TTGT ACACT TCC 1 TT GCCGT GAA ACT GAGCAAC TCC TC TC 1 TT GCCGT GAA ACT GAGCAAC TCT GAGCCAC TCC TC TC 51 GO TGACCCAC AT ACA CTCAT ACT TA CA DT G GT G GT G GT G 51 GO TGACCCAC AT ACA CTCAT<!--</td--><td>1 11 21 31 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT GCT 1 TT GCCAT GGA ACT GAGCACC TTTGT GACCCAC GTTGACCCAC 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT G</td><td>1 11 21 31 1 1 TT GCCAT GGA ACT GAG SCAC TTTTT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTTT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TCT GT GACCCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTGT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTGT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCGGT GACCCAC
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGGT GACCCAC TCGT TCGT GAT
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGT GAGCCAC TCGT TCGT GAT
1 TT GCGT GAGCCAC TCGT TGGT GAT
1 TT GCGT GAGCCAC TCGT TGGT GAT
1 TT GCGT GAGCCAC TCGT TT GGAT GAG TCGT GAGT GA</td><td>1 1.1 2.1 3.1 1 1.1 1.1 2.1 3.1 1 1.1 1.1 1.1 2.1 3.1 1 1.1</td><td>1 11 21 31 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCGT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCGT TCCTGGAG 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT CC GO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT CC CO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT C C CO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT C GT C C CO</td><td>1 11 21 31 1<td>1 11 21 31 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT TT GACCT TCCT GGAGGT 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTG GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGCAG 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GAGCCAC TCGT GACCT 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 51 GT GACCCAC AT ACA CT CT CT ACT TA CA GT GAT ACT TA CA GT GAT 51 GT GACCCAC AT A</td><td>1 11 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1<td>1 11 21 31 41 1<td>1 11 21 31 41 1
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1<td>1 11 21 31 41 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT GCAGGCAC TCTTTTTGACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGCACGT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACGCAC TCCTG GAGGAGC AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCCT TCCTGGAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGAGGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TT CCGT GAGCAGGA AGACC 51 GT GACCCAC AT ACCA GT CAT ACT T ACA GT G GT CCG GA GA G GT CCG</td><td>1 11 21 31 41 1<td>1 11 21 31 41 1 1 1 1 1 1 1 41 1<td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1<!--</td--><td>1 11 11 21 31 41 1<</td></td></td></td></td></td></td></td></td> | 1 11 21 3 1 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT T 1 TT GCCGT GAA ACT GAGGCAC TTTGT GACCT T 1 TT CCCGT GAA ACT GAGGCAC TTTGT ACT T 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACT T 1 TT CCCGT GAA ACT GAGGAAC TTTTGT ACT T 51 GT GACCCAC AT ACACT CAAT 51 GT GACCCACC | 1 11 21 31 1 1 TT GCCAT GGA ACT GAGGCAC TTT TT TT GCCAT GGA ACT GAGGCAC TTT GCCAT GGA ACT GAGGCAC TTT GT GACCT TC 1 TT GCCAT GGA ACT GAGGCAC TTT GT GACCT TC TT TT GCCAT GGA ACT GAGGCAC TTT GT GACCT TC 1 TT GCCAT GGA ACT GAGGCAC TT TT GT GACCT TC TT TT GT GACCCT TT TT GT GACCCAC TT < | 1 1.1 2.1 3.1 1 1.TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCC 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCC 1 TT GCCGT GAA ACT GAGGCAC TTTGTAACCT TCC 1 TT GCCGT GAA ACT GAGGCAC TTGT ACACT TCC 1 TT GCCGT GAA ACT GAGGCAC TTGT ACACT TCC 1 TT GCCGT GAA ACT GAGCAAC TCC TC TC 1 TT GCCGT GAA ACT GAGCAAC TCT GAGCCAC TCC TC TC 51 GO TGACCCAC AT ACA CTCAT ACT TA CA DT G GT G GT G GT G 51 GO TGACCCAC AT ACA CTCAT </td <td>1 11 21 31 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT GCT 1 TT GCCAT GGA ACT GAGCACC TTTGT GACCCAC GTTGACCCAC 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT G</td> <td>1 11 21 31 1 1 TT GCCAT GGA ACT GAG SCAC TTTTT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTTT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TCT GT GACCCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTGT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTGT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCGGT GACCCAC
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGGT GACCCAC TCGT TCGT GAT
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGT GAGCCAC TCGT TCGT GAT
1 TT GCGT GAGCCAC TCGT TGGT GAT
1 TT GCGT GAGCCAC TCGT TGGT GAT
1 TT GCGT GAGCCAC TCGT TT GGAT GAG TCGT GAGT GA</td> <td>1 1.1 2.1 3.1 1 1.1 1.1 2.1 3.1 1 1.1 1.1 1.1 2.1 3.1 1 1.1</td> <td>1 11 21 31 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCGT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCGT TCCTGGAG 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT CC GO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT CC CO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT C C CO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT C GT C C CO</td> <td>1 11 21 31 1<td>1 11 21 31 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT TT GACCT TCCT GGAGGT 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTG GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT
 TCCT GGAGGCAG 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GAGCCAC TCGT GACCT 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 51 GT GACCCAC AT ACA CT CT CT ACT TA CA GT GAT ACT TA CA GT GAT 51 GT GACCCAC AT A</td><td>1 11 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1<td>1 11 21 31 41 1<td>1 11 21 31 41 1<td>1 11 21 31 41 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT GCAGGCAC TCTTTTTGACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGCACGT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACGCAC TCCTG GAGGAGC AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCCT TCCTGGAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGAGGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TT CCGT GAGCAGGA AGACC 51 GT GACCCAC AT ACCA GT CAT ACT T ACA GT G GT CCG GA GA G GT CCG</td><td>1 11 21 31 41 1<td>1 11 21 31 41 1 1 1 1 1 1 1 41 1<td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1<!--</td--><td>1 11 11 21 31 41 1<</td></td></td></td></td></td></td></td> | 1 11 21 31 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT TCCT 1 TT GCCAT GGA ACT GAGGCACC TTTGT GACCT GCT 1 TT GCCAT GGA ACT GAGCACC TTTGT GACCCAC GTTGACCCAC 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT GACCCACC AT ACACTCAT ACT T ACAOTC GTCG 51 GT G | 1 11 21 31 1 1 TT GCCAT GGA ACT GAG SCAC TTTTT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTTT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TCT GT GACCCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTGT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GCAC TTTGT GACCT TCCT GG
1 TT GCCAT GGA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCCGT GAA ACT GAG GGAC TCT GT ACCT TCGT GG
1 TT GCGGT GACCCAC
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGGT GACCCAC TCGT TCGT GAT
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGGT GACCCAC TCGT GAT
1 TT GCGT GAGCCAC TCGT TCGT GAT
1 TT GCGT GAGCCAC TCGT TGGT GAT
1 TT GCGT GAGCCAC TCGT TGGT GAT
1 TT GCGT GAGCCAC TCGT TT GGAT GAG TCGT GAGT GA | 1 1.1 2.1 3.1 1 1.1 1.1 2.1 3.1 1 1.1 1.1 1.1 2.1 3.1 1 1.1 | 1 11 21 31 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTTTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGTGACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCGT TCCTGGAG 1 TT CCCGT GAA ACT GAGGAAC TTTGT ACCGT TCCTGGAG 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT CC GO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT CC CO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT G GT C C CO AC 51 GT GACCCAC AT ACA CTCAT ACT T ACA OT C GT C C CO | 1 11 21 31 1 <td>1 11 21 31 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT TT GACCT TCCT GGAGGT 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC
TTTG GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGCAG 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GAGCCAC TCGT GACCT 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 51 GT GACCCAC AT ACA CT CT CT ACT TA CA GT GAT ACT TA CA GT GAT 51 GT GACCCAC AT A</td> <td>1 11 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1<td>1 11 21 31 41 1<td>1 11 21 31 41 1<td>1 11 21 31 41 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT GCAGGCAC TCTTTTTGACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGCACGT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACGCAC TCCTG GAGGAGC AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCCT TCCTGGAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGAGGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TT CCGT GAGCAGGA AGACC 51 GT GACCCAC AT ACCA GT CAT ACT T ACA GT G GT CCG GA GA G GT CCG</td><td>1 11 21 31 41 1<td>1 11 21 31 41 1 1 1 1 1 1 1 41 1<td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1<!--</td--><td>1 11 11 21 31 41 1<</td></td></td></td></td></td></td> | 1 11 21 31 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT TT GACCT TCCT GGAGGT 1 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTTT GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTG GACCT TCCT GGAGGT 1 TT GCCAT GGA ACT GAGGCAC TTTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGCAG 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GACCT TCCT GGAGGT 1 TT GCCGT GAA ACT GAGGCAC TTG GAGCCAC TCGT GACCT 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 1 TT GCCGT GAA ACT GAGGCAC TCGT GACCT TCCT GGAGCAC 51 GT GACCCAC AT ACA CT CT CT ACT TA CA GT GAT ACT TA CA GT GAT 51 GT GACCCAC AT A | 1 11 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 1 1 1 21 31 4 1 <td>1 11 21 31 41 1<td>1 11 21 31 41 1<td>1 11 21 31 41 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT GCAGGCAC TCTTTTTGACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGCACGT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACGCAC TCCTG GAGGAGC AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCCT TCCTGGAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGAGGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TT CCGT GAGCAGGA AGACC 51 GT GACCCAC AT ACCA GT CAT ACT T ACA GT G GT CCG GA GA G GT CCG</td><td>1 11 21 31 41 1
 1 1<td>1 11 21 31 41 1 1 1 1 1 1 1 41 1<td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1<!--</td--><td>1 11 11 21 31 41 1<</td></td></td></td></td></td> | 1 11 21 31 41 1 <td>1 11 21 31 41 1<td>1 11 21 31 41 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT GCAGGCAC TCTTTTTGACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGCACGT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACGCAC TCCTG GAGGAGC AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCCT TCCTGGAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGAGGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TT CCGT GAGCAGGA AGACC 51 GT GACCCAC AT ACCA GT CAT ACT T ACA GT G GT CCG GA GA G GT CCG</td><td>1 11 21 31 41 1<td>1 11 21 31 41 1 1 1 1 1 1 1 41 1<td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1<!--</td--><td>1 11 11 21 31 41 1<</td></td></td></td></td> | 1 11 21 31 41 1 <td>1 11 21 31 41 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT GCAGGCAC TCTTTTTGACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGCACGT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACGCAC TCCTG GAGGAGC AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCCT TCCTGGAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGAGGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TT CCGT GAGCAGGA AGACC 51 GT GACCCAC AT ACCA GT CAT ACT T ACA GT G GT CCG GA GA G GT CCG</td> <td>1 11 21 31 41 1<td>1 11 21 31 41 1 1 1 1 1 1 1 41 1<td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1
1 1<!--</td--><td>1 11 11 21 31 41 1<</td></td></td></td> | 1 11 21 31 41 1 TT GCCAT GGA ACT GAGGCAC TTTTTTGACCT GCAGGCAC TCTTTTTGACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTTTGCACGT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACCT TCCTGGAGGT AGAGC 1 TT GCCAT GGA ACT GAGGCAC TTTGT GACGCAC TCCTG GAGGAGC AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCCT TCCTGGAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGAGGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TCTGT ACCGT GAGGAGT AGAGC 1 TT CCCGT GAA ACT GAGGAAC TT CCGT GAGCAGGA AGACC 51 GT GACCCAC AT ACCA GT CAT ACT T ACA GT G GT CCG GA GA G GT CCG | 1 11 21 31 41 1 <td>1 11 21 31 41 1 1 1 1 1 1 1 41 1<td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1<!--</td--><td>1 11 11 21 31 41 1<</td></td></td> | 1 11 21 31 41 1 1 1 1 1 1 1 41 1 <td>1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1<!--</td--><td>1 11 11 21 31 41 1<</td></td> | 1 11 21 31 41 1 1 1 1 1 41 1 1 1 1 1 1 41 1 </td <td>1 11 11 21 31 41 1<</td> | 1 11 11 21 31 41 1< |

S. Lomvardas, G. Barnea, D. J. Pisapia, M. Mendelsohn, J. Kirkland, and R. Axel. Interchromosomal interactions and olfactory receptor choice. *Cell* 126 (2):403-413, 2006.

F. Savarese and R. Grosschedl. Blurring cis and trans in gene regulation. *Cell* 126 (2):248-250, 2006.

Chromosome Conformation Capture (3C) Reveals the Association of the H Enhancer with Olfactory Receptor Genes



OMP and CNG: 2 genes highly expressed in olfactory sensory neurons

Pair

From Lomvardas, S. et al. Cell, 126:403-413, 2006.

Monoallelic OR Gene Expression in Sensory Neurons



(A) Association of the *H* enhancer with a single OR promoter in cis or in trans mediates monoallelic OR gene expression in sensory neurons. Depicted are three different olfactory neurons in which the H enhancer, located on chromosome 14, interacts either with an OR gene in cis (for example, MOR28 on chromosome 14) or, alternatively, with an OR gene in trans (for example, M50 on chromosome 7 or M71 on chromosome 9). The enhancer is shown as a multiprotein complex, and the OR gene promoters are shown as colored boxes; active transcription is represented by an arrow.

(B) Model for the feedback regulation elicited by the expression of a functional OR gene. Upon interaction with an odorant, the OR transmits either a positive signal that strengthens the association between the *H* enhancer and the OR gene promoter or a negative signal that prevents the activation of the second H allele, possibly by DNA methylation of the H enhancer. Currently, it is unclear whether DNA methylation inactivates or activates the H enhancer.

The *H* enhancer, a single copy DNA element, is located 75 kb upstream of the *MOR28* gene cluster on chromosome 14. It can cooperate with OR gene promoter as little as 161 bp of 5'-flanking DNA sequences.

From Savarese, F. and Grosschedl, R. Cell, 126:248-250, 2006.

Few other published examples of physical and functional evidences for nonallelic interaction between chromosomes:

• An LCR in IFN-γ locus associated with IL-4 locus on a different chromosome in committed naive T (*Spilianakis et al., Nature, 435:637-645, 2005*).

• The imprinting control region of the Igf2/H19 locus and the Wsb1/Nf1 gene (*Ling et al., Science, 312:269-272, 2006*).

These nonallelic interchromosomal interactions appear relatively infrequent and transient, and their biological role is still somewhat unclear...

Regulatory region databases

PromoSer: The mammalian promoter service http://biowulf.bu.edu/zlab/PromoSer

ORegAnno Open Regulatory Annotation: http://www.oreganno.org

PAZAR: A public database of transcription factor and regulatory sequence annotation http://www.pazar.info

Regulatory region analysis

PIPMaker: http://pipmaker.bx.psu.edu/pipmaker VISTA Tools: mVISTA and rVISTA http://genome.lbl.gov/vista/

DCODE.org Comparative Genomics Center: Comparing genomes to decipher the code of gene regulation http://www.dcode.org

Genomatix software GmbH: http://www.genomatix.de

General databases and tools

UCSC Genome Browser: http://genome.ucsc.edu

IdConvert:

Galaxy website: http://www.bx.psu.edu/cgi-bin/trac.cgi

http://idconverter.bioinfo.cnio.es

En forme de conclusion...

Hypothesis-driven approach

Avoid fishing expeditions

- Do not expect to find a needle in a haystack
- Do not expect the answer to pop out of the target gene list
- Do not expect mechanistic insights
- Envision specific outcomes and test them directly
 - Use literature knowledge
 - Does target gene binding change between conditions, mutant backgrounds, or subunits?

Do not expect perfect outcomes

- Binding to a gene does not always correlate with expression level

INSERM UMR599 Cancer Research Center of Marseille - Director : Francoise Birg **Transcription Team Michèle Algarté Pierre Cauchy Régis Costello Brigitte Kahn-Perlès Guoqiang Hua** Patrick Lécine **Carol Lipcey** Pascal Rameil Frédéric Rosa Jung-Hua Yeh **Bing Zhu** Jean Imbert Immunology Team **Chantal Cerdan Jacques Nunès Daniel Olive** Gene & Cellular Therapy Team Thomas Moreau **Christian Chabannon Cécile Tonnelle Oncology Team** José Adelaïde **Daniel Birnbaum**

Immunology Center of Marseille-Luminy Salvatore Spicuglia Sanjeev Kumar **Pierre Ferrier INSERM U363, Paris Fabrice Gouilleux Curie Institute, Orsay Jacques Ghysdael ISREC**, Lausanne **Philip Bücher Markus Nabholz ICRF**, London **Carol Beadling Doreen Cantrell Genzentrum, Martinsried Patrick Baeuerle** TAGC, INSERM EMI206, Marseille **Béatrice Loriod Benoît Ballester** Rémi Hougatte NHLBI/NIH **Hyoung Pio Kim** Warren Leonard



Special Bonus

UCSC Genome Browser on Human Mar. 2006 Assembly position/search: chr10:6,080,616-6,159,203



Genomic Targets Identification of Specific Transcription Factors Using Chromatin Immunoprecipitation



ChIP-on-chip

ChIP-on-chip with whole-genome oligo arrays



- Whole-genome arrays
 - 60mer every < 300 bp
 - Oligo selected by uniqueness, GC content, complexity, selfbinding potential
- Peak finding algorithm
 - Based on expected peak curve
 - Voting of three consecutive probes

Strategies for the Design of Microarrays for the Human Genome



CpG islands

Weinmann et al. (2002) Genes & Dev. 16:235-244 Oberley et al. (2004) Methods Enzymol. 376:315-334

- CpG dinucleotides are present at 20% of predicted frequency
- CpG islands: >200 bp long, >50 %G+C, CpG >0.6 predicted
- CpG islands account for 1% of the genome
- 29,000 CpG islands are predicted in the human genome
- ~60% of known genes have a CpG island near 5' end
- CpG island microarrays are promoter- and regulatory region-enriched arrays

29,000 CpG islands are predicted in the human genome

In progress analysis of a chip with ~200 human promoter regions and ~4 000 CpG islands ChIP anti-Ets-1/2



La Londe les Maures 12 May 2005. Rémi Houlgatte « Chromatin Profiling of Human Pathologies »

From Rémi Houlgatte – INSERM ERM206, Marseille, France

Ets Factor Binding Site (EBS)



La Londe les Maures 12 May 2005. Rémi Houlgatte « Chromatin Profiling of Human Pathologies »

Alternative Approaches...
DamID: in vivo mapping of protein-genome interactions



From Bas van Steensel, Netherland Cancer Institute

	DamID	versus	ChIP-on-chip
•	No antibody required	•	Highly specific antibody needed
ŝ.	Works for >90% of all proteins tested		Success rate?? – Depends on antibody, epitope exposure and "crosslinkability"
•	Fusion protein may not be fully functional		Crosslinking artefacts?
3 - 22	Cannot map post-translational modification	ns •	Mapping of e.g. histone modifications
•	Studies of mutated proteins	•	More difficult, need epitope tagging and precisely controlled expression
•	One fruitfly or one 35mm dish of cells is enough		Amount of material required?
•	Low time-resolution (hrs)		High time-resolution (min)
ו*	Mapping resolution ~1-2kb?? – may depend on local chromatin conformation	•	Mapping resolution 0.5-1kb??? – may depend on local chromatin conformation

But: which one is "better" in practice? More importantly: do the two methods give the same results?

From Bas van Steensel, Netherlands Cancer Institute, Amsterdam

Alternative approaches

<u>Genome-Wide Mapping Technique (GMAT)</u> Or <u>Serial Analysis of Chromatin Occupancy (SACO)</u>



From T. Y. Roh, W. C. Ngau, K. Cui, D. Landsman, and K. Zhao. High-resolution genome-wide mapping of histone modifications. Nat Biotechnol. 22 (8):1013-1016, 2004.

Functional Effects of Histone Modifications on Transcription A Few Examples in Mammals

- Acetylation at lysine residues is highly associated with transcriptional activation (H2AK5, H2BK12, H3K9/K14, etc.)
- Methylation at lysine or arginine residues is associated with either transcriptional activation (H3K4me3, H4R3, etc.) or repression (H3K9, H3K27me3, etc.)
- Phosphorylation at serine or threonine residues is associated with either transcriptional activation (H3S28, etc.) or repression (H2AS1, etc.)

Ubiquitylation and sumoylation have been associated with mitosis, meiosis, etc.

For a continuous update: www.histone.com

From C. L. Peterson and M. A. Laniel. Histones and histone modifications. Curr.Biol. 14 (14):R546-R551, 2004.

Major Nucleosomal Histone Modification Mapping



From G. Felsenfeld and M. Groudine. Controlling the double helix. Nature 421 (6921):448-453, 2003.

Quelques infos utiles

Site web de l'atelier INSERM « Epigénomique : analyse à grande échelle des modifications de la chromatine et des interactions entre génomes et facteurs régulateurs de la transcription » 12-13 mai 2005, La Londe Les Maures et 16-20 mai 2005, Marseille http://gin.univ-mrs.fr/~denis/Epigenomics/

Grange, T., Imbert, J. and Thieffry, D. Epigenomics: large scale analysis of chromatin modifications and transcription factors/genome interactions. *BioEssays* 27:1203-1205, 2005.

Site web « ChIP-on-chip » à partir des travaux de Bing Ren, Laboratory of Gene Regulation, Ludwig Institute for Cancer Research, UCSD http://www.chiponchip.org/ Vous y trouverez des protocoles, une liste d'anticorps validés pour ChIP et ChIPon-chip, des références, etc.

Site web Ecole-Chercheurs INRA « La phylogénomique : une aide à l'étude des grandes fonctions du vivant »

12-14 décembre 2006, Carry-le-Rouet

http://www.inra.fr/internet/Projets/agroBI/PHYLO.html

Resources

Companies offering genome-wide or customize oligo and/or promoter chips

- 1) Agilent: <u>www.home.agilent.com</u>
- 2) Affymetrix: <u>www.affymetrix.com</u>
- 3) Nimblegen Systems: <u>www.nimblegen.com</u>
- 4) Aviva Systems Biology: <u>www.avivasysbio.com</u>
- 5) human and mouse CpG islands: Microarray Centre, University Health Network, Toronto, <u>www.microarrays.ca</u>

The ChIP-GLAS Technology



articles Nature 434 (7031):338-345, 2005.

Systematic discovery of regulatory motifs in human promoters and 3⁷ UTRs by comparison of several mammals

Xiaohui Xie¹, Jun Lu¹, E. J. Kulbokas¹, Todd R. Golub¹, Vamsi Mootha¹, Kerstin Lindblad-Toh¹, Eric S. Lander^{1,2}* & Manolis Kellis^{1,3}*

¹Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02141, USA

²Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02139, USA

³Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

*These authors contributed equally to this work

Comprehensive identification of all functional elements encoded in the human genome is a fundamental need in biomedical research. Here, we present a comparative analysis of the human, mouse, rat and dog genomes to create a systematic catalogue of common regulatory motifs in promoters and 3' untranslated regions (3' UTRs). The promoter analysis yields 174 candidate motifs, including most previously known transcription-factor binding sites and 105 new motifs. The 3'-UTR analysis yields 106 motifs likely to be involved in post-transcriptional regulation. Nearly one-half are associated with microRNAs (miRNAs), leading to the discovery of many new miRNA genes and their likely target genes. Our results suggest that previous estimates of the number of human miRNA genes were low, and that miRNAs regulate at least 20% of human genes. The overall results provide a systematic view of gene regulation in the human, which will be refined as additional mammalian genomes become available.

- 1. Whole genome alignment of 4 mammalian genomes: human, mouse, rat, dog
- 2. Extraction aligned promoter and 3' UTR using RefSeq annotations

17 700 Refseq68 Mb promoter dataset15 Mb 3' UTR123 Mb intronic sequence as control dataset: last 2 introns

Proportion of aligned bases between 4 species: Promoters 51% (44% upstream, 58% downstream TSS) 3' UTR 73% Control dataset 34% Whole genome 28%



8-mer TGACCTTG: Err- α binding site (estrogen-related receptor alpha)

434 occurrences in human promoter regions, 162 conserved across all 4 species 37% conservation rate compared to 8% for a random 8-mer motif in promoter dataset and 6.2% in control dataset

MCS: motif conservation score, represents the number of standard deviations (s.d.) by which the observed conserved rate of a motif exceeds the expected conservation rate of comparable motifs (Ex.: MCS for Err-α is 25.2 s.d.
446 mammalian motifs in TRANSFAC clustered in 123 motif clusters based on sequence similarity 63% MCS>3, including 50% MCS>5, compared to only 1.6% with MCS>3 control set
3' UTR few motifs defined: polyadenylation signal AATAAA, 6 617 conservation versus 14 266 occurrences 46%, MCS 135 compared to 10% for a control random motif in 3' UTR and 6% in intronic controls

Screening for <u>Highly</u> <u>Conserved</u> 6-18-mer <u>Motifs</u> with MCS>6 (10¹² possible occurrences)

Promoters: 174 HCM including 59 strong matches with known consensus and 10 weaker 72% of the 123 TRANSFAC clusters (5% matches for a random set)
 105 potential new regulatory motifs, for example M₄ (ACTAYRNNNCCCR) occurs 520 times, 317 conserved across 4 species (61%)

No.	Discovered motif	MCS	Known factor	Conservation rate †	Tissue enrichment‡	Position bias§
1	ROGCAnGOGY	107.8	NRF-1	0.49	15.0	-62
2	CACGTG	85.3	MYC	0.47	8.8	-62
3	SOGGAAGY	80.4	ELK-1	0.44	22.4	-24
4	ACTAYRnnnOOOR	69.5	-	0.61	8.1	-89
5	GATTGGY	64.6	NF-Y	0.51	9.8	-63
6	GGGCGGR	63.9	SP1	0.21	11.4	-63
7	TGAnTCA	62.8	AP-1	0.38	6.5	-
8	TMTCGCGAnR	55.7	-	0.64	9.4	-62
9	TGAYRTCA	55.7	ATF3	0.50	6.1	-66
10	GCCATnTTG	54.7	YY1	0.72	12.2	-
11	MGGAAGTG	51.6	GABP	0.43	13.9	-23
12	CAGGTG	47.6	E12	0.26	9.9	-
13	CITTGT	46.0	LEF1	0.42	13.6	-
14	TGACGTCA	44.8	ATF3	0.44	4.2	-22
15	CAGCTG	43.9	AP-4	0.27	8.9	-
16	BYTTCCTG	43.0	C-ETS-2	0.32	7.4	-24
17	AACTIT	42.1	IBF1	0.43	11.1	_
18	TCAnnTGAY	40.4	SREBP-1	0.47	4.9	-64
19	GKCGCn(7)TGAYG	40.1	-	0.35	5.6	-62
20	GTGAOGY	38.4	E4F1	0.34	6.6	-56
21	GGAAnOGGAAnY	37.7		0.68	7.0	-33
22	TGOGCAnK	37.4	-	0.24	8.2	-17
23	TAATTA	37.3	CHX10	0.29	7.1	_
24	GGGAGGRR	33.5	MAZ	0.16	9.4	-
25	TGACCTY	33.4	ESBBA	0.30	7.7	-
26	TTAYRTAA	32.6	F4BP4	0.34	61	-
27	TGGn/6)KCCAR	32.3	-	0.27	4.5	-
28	CTAWWWATA	32.3	BSBEC4	0.36	7.6	-
29	CTTTAAR	30.8	-	0.43	54	-
30	YGOGYBOGC	30.5	_	0.19	5.9	-31
31	GGGYGTGyY	30.0	_	0.24	5.4	-63
32	TGASTMAGC	27.2	NE-E2	0.39	5.4	-66
33	VTATTTTDB	26.4	MEE-2	0.00	7 1	-
34	CYTAGCAAY	26.1	-	0.50	52	- 142
35	OCAnCTOnY	25.7	MYOD	0.25	8.2	142
36	BTAAACA	25.6	EREAC-2	0.46	7.0	_
37	GTTBYCATER	25.0	-	0.40	7.6	-56
38	TGACCTTG	25.0	EBB-4	0.37	81	-
30	TOCOPERATION	20.2	Enn-a	0.30	0.1 6 0	
40	TOV-BGAA	24.3	CTA TEA	0.10	8.8	-00
40	TGACAGeV	24.3	MEIST	0.13	69	
42	TGACATY	23.8		0.23	5.8	_
42		23.0	-	0.23	5.8	- 57
43	VATO-MAAT	23.1		0.47	4.7	-57
44		23.3	001-2	0.00	0.9	101
40	WITCHOTO	23.4	-	0.47	Ē	- 101
40	TOOOAAD	23.0		0.20	5.0	-63
41		22.9		0.25	7.0	-
+0	GUGINANTICU	22.8	C-HEL	0.30	6.0	- 12
49	CATIGTYY	22.5	SOX-9	0.43	5.8	-
50	HGAGGAARY	22.4	PU.1	0.22	4.0	-

*Name of the best-matching motif in TRANSFAC database, if any. Weak matches are indicated in italics.

†The percentage of human motif occurrences that match the motif consensus across all four species.

#A measure of the maximum enrichment of conserved motif occurrences upstream of genes expressed in a compendium of 75 human tissues.

§For motifs with strong positional bias (score > 5 s.d.), the mode of the distance distribution upstream of the TSS.

Biological significance

 Positional bias of the motif relative to TSS: consistent with a role in transcription initiation
 28% for known motifs and 35% for now

28% for known motifs and 35% for new

Overall 89% of known and 69% of new motifs show tissue specificity, positional bias or both



3' UTR

- 1. Strong directional bias (mRNA regulatory elements)
- 2. Unusual length distribution (8-mer preference)



Tabl	Table 2 Top 50 conserved 8-mers in 3' UTRs and corresponding miRNAs						
No.	Motif	Conservation rate	MIRNA*				
1	GTGCAATA	0.55	miR-92, miR-32, miR-137, miR-367, miR-25, miR-217(t), new(12)				
2	GTGCCTTA	0.54	miR-124a, miR-224(†), miR-208(†), miR-34b(†), miR-9*(†), miR-34c(†), miR-330(†), new(6)				
3	CTACCTCA	0.53	miR-98, let-7i, let-7g, let-7f, let-7c, let-7c				
		0.40	new(4)				
4	ACCAAAGA	0.49	miR-9, new(11) miR-20a En miR-20d miR-20a miR-20h				
5	IGITIAGA	0.48	miR-30e-5p, miR-30d, miR-30c, miR-30b, miR-30a-5p, new(4)				
6	GCACTTTA	0.48	miR-20, miR-106b, miR-18(†), miR-93, miR-372, miR-17-5p, miR-106a, miR-302d, miR-302c, miR-302b, miR-302a, miR-373, new(4)				
7	TGGTGCTA	0.43	miR-29c, miR-29b, miR-29a, miR-107(†), miR-103(†), new(6)				
8	CTATGCAA	0.42	miR-153, new(9)				
9	TACTTGAA	0.42	miR-26b, miR-26a, new(4)				
10	CGCAAAAA	0.42	New(2)				
11	GTGCCAAA	0.41	miR-96, miR-182, miR-183, new(16)				
12	GTACTGTA	0.40	miR-101, miR-199a‡, miR-144, new(2)				
13	ATACGGGT	0.40	miR-99a, miR-100, miR-99b(†)				
14	AAGCACAA	0.40	miR-218, new(8)				
15	TTTGCACT	0.37	miR-19b, miR-19a, miR-301, miR-130b,				
			miR-130a, miR-152, miR-148b, miR-148a, miR-139, new(10)				
16	TGTACATA	0.36	-				
17	AAGCCATA	0.35	miR-135b, miR-135a				
18	ACTGTGAA	0.35	miR-27b, miR-27a, miR-128b, miR-128a, miR-23b(†), miR-23a(†), new(5)				
19	AGACAATC	0.33	miR-219, new(2)				
20	TGCTGCTA	0.33	miR-195, miR-16, miR-15b, miR-15a, miR-338(†), miR-424, new(5)				
21	TTTTGTAC	0.32	New(1)				
22	ACATTCCA	0.32	miR-206, miR-1, miR-122a(†)				
23	TGAATGTA	0.31	miR-181b(†), miR-181c, miR-181a				
24	ACGGTACA	0.30	-				
25	CAGTATTA	0.30	miR-200c, miR-200b, new(1)				
26	TTGCATGT	0.29	New(7)				
27	TCGCATGA	0.29	New(1)				
28	CTCAGGGA	0.29	miR-125b, miR-125a, new(6)				
29	CAAGTGCC	0.28	New(2)				
30	ACTACTGA	0.28	-				
31	TGGACCAA	0.28	miR-133b, miR-133a, new(3)				
32	GTAAATAG	0.28	New(1)				
33	TGTAGATA	0.28	-				
34	ACACTACA	0.27	miR-142-3p, new(3)				
35	GTACAGTT	0.26	New(1)				
36	CACCAGCA	0.26	miR-138(†), new(4)				
37	GGTACGAA	0.25	miR-126(†)				
38	TGTATAGT	0.24	miR-381				
39	AAGGGCTA	0.24	New(1)				
40	AGCTITAA	0.24	New(1)				
41	ATTIATCG	0.23	-				
42	GGCAGCTA	0.23	miR-22(†), new(1)				
43	GUIGTAAA	0.23	New(4)				
44	GCACTAAT	0.22	-				
45	AAAGGIGC	0.22	-				
46	AIGIAGCA	0.22	miR-221(†), miR-222(†)				
4/	ACACIGGA	0.21	miR-1990(T), miR-199a(T), miR-145(T), new(2)				
48	TTTOATAA	0.21					
49 50	AAGCATGC	0.21	New(1)				

Top 50 of 72 highly conserved 8-mer motifs in 3' UTRs and their corresponding mIRNAs. *Known human mIRNAs matching complements of each 8-mer and its variants grouped in the same cluster. The dagger symbol (in parentheses) indicates mIRNAs with one mismatch. When multiple new mIRNAs are discovered using the 8-mer motifs as seeds, their number is indicated in parentheses. [See Supplementary Information for full alignments of known and discovered mIRNAs.]

\$ The miRNA mature product comes from the 3' arm of the stem loop.